

MISSISSIPPI DIVISION OF MEDICAID UNIVERSAL PREFERRED DRUG LIST

EFFECTIVE 6/1/2026
VERSION 2026_7
Updated 5/15/2026

General Preferred Drug List Information

- Gainwell Technologies DUR+ process is a proprietary electronic prior authorization system used for Medicaid pharmacy claims.
- Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
- **PREFERRED BRANDS** will not count toward the two-brand monthly Rx Limit.
- Drugs highlighted in **yellow** denote change in PDL status.
- To search the PDL, **press CTRL + F**.

Medication Coverage Status Search Tool - [Pharmacy Drug Coverage Inquiry](#)

ACNE AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTI-INFECTIVES		<p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 21 years: all acne agents except isotretinoin products <p>Topical Clindamycin 1% lotion</p> <ul style="list-style-type: none"> • 21 years and older AND • Documented diagnosis of hidradenitis suppurativa <p>Note: Isotretinoin products available for all ages Clindamycin 1% lotion only available for ages 21 years and older with approvable diagnosis Preferred clindamycin 1% lotion for ages < 21 years does not require PA</p>
clindamycin gel (generic CLEOCIN-T)	azelaic acid	
clindamycin lotion, medicated swab, solution	CLEOCIN T (clindamycin)	
erythromycin gel, solution	CLINDACIN (clindamycin)	
	clindamycin foam	
	clindamycin gel (generic CLINDAGEL)	
	dapsone	
	ERY (erythromycin)	
	MORGIDOX (doxycycline)	
	sulfacetamide sodium suspension	
	WINLEVI (clascoterone) cream	
ISOTRETINOIN PRODUCTS		
AMNESTEEM (isotretinoin)	ABSORBICA (isotretinoin)	
CLARAVIS (isotretinoin)	isotretinoin	
ZENATANE (isotretinoin)		
KERATOLYTICS (BENZOYL PEROXIDES)		
ACNE MEDICATION (benzoyl peroxide)	BPO towelette (benzoyl peroxide)	
benzoyl peroxide		
RETINOIDS		
adapalene gel, gel with pump	adapalene cream	
tretinoin cream	AKLIEF (trifarotene)	
	ATRALIN (tretinoin)	
	DIFFERIN (adapalene)	
	FABIOR (tazarotene)	
	tretinoin gel	
	tretinoin microsphere	
OTHERS/COMBINATION PRODUCTS		
adapalene/benzoyl peroxide gel	CLEANSING WASH (sulfacetamide sodium/sulfur/urea) cleanser	
clindamycin/benzoyl peroxide 1%-5% gel	clindamycin phosphate/benzoyl peroxide 1.2%-2.5% gel	
clindamycin phosphate/benzoyl peroxide 1.2%-5% gel	clindamycin/benzoyl peroxide 1.2%-3.75% gel w/pump (generic ONEXTON)	
sodium sulfacetamide w/sulfur 8%-4%, 9%-4.25%, 10-5% suspension	clindamycin phosphate/tretinoin 1.2%-0.025% gel	

	EPIDUO FORTE (adapalene/benzoyl peroxide) gel	
	erythromycin/benzoyl peroxide gel	
	NEUAC (benzoyl peroxide/clindamycin) cream, gel	
	sodium sulfacetamide w/sulfur 9.8%-4.8%	
	sodium sulfacetamide w/sulfur 10%-2% cream	
	sodium sulfacetamide w/sulfur 10%-5% cream, lotion	
	SSS (sodium sulfacetamide/sulfur)10-5 cream, foam	
	TWYNEO (benzoyl peroxide/tretinoin) cream	

ALPHA-1 PROTEINASE INHIBITORS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ARALAST NP		
GLASSIA		
PROLASTIN C		
ZEMAIRA		

ALZHEIMER'S AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CHOLINESTERASE INHIBITORS		<p>Preferred Criteria</p> <ul style="list-style-type: none"> Documented approvable diagnosis <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> Documented approvable diagnosis AND Have tried 2 different preferred agents in the past 6 months <p>NAMZARIC</p> <ul style="list-style-type: none"> Requires clinical review <p>ZUNVEYL</p> <ul style="list-style-type: none"> Requires clinical review
donepezil 5 mg, 10 mg ODT, tablets		
galantamine	ARICEPT (donepezil)	
galantamine ER	donepezil 23 mg tablet	
rivastigmine	EXELON (rivastigmine)	
	ZUNVEYL (benzgalantamine gluconate)	
NMDA RECEPTOR ANTAGONISTS		
memantine	memantine ER	
	NAMENDA XR (memantine ER)	
COMBINATION AGENTS		
	memantine/donepezil ER	
	NAMZARIC (memantine/donepezil)	

ANALGESICS, OPIOID-SHORT ACTING ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
------------------	----------------------	-------------

acetaminophen/caffeine/dihydrocodeine		<p>MS DOM Opioid Initiative Criteria details found here</p> <ul style="list-style-type: none"> • Morphine Equivalent Daily Dose • Concomitant use of Opioids and Benzodiazepines <p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: codeine-containing products and tramadol-containing products <p>Quantity Limit (per 31 rolling days)</p> <ul style="list-style-type: none"> • 62 tablets: butalbital/codeine combinations, codeine combinations, dihydrocodeine combinations, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, oxycodone, oxymorphone, pentazocine, tapentadol, tramadol • 186 tablets: butalbital/acetaminophen, butalbital/aspirin • 5 mL: butorphanol nasal • 180 mL: oxycodone liquid • 280 mL: QDOLO <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
acetaminophen/codeine	ASCOMP WITH CODEINE (aspirin/butalbital/caffeine/codeine)	
codeine	aspirin/butalbital/caffeine/codeine	
ENDOCET (oxycodone/acetaminophen)	butalbital/acetaminophen/caffeine/codeine	
hydrocodone/acetaminophen	butorphanol	
hydromorphone	carisoprodol/aspirin/codeine	
morphine sulfate	DILAUDID (hydromorphone)	
oxycodone		
oxycodone/acetaminophen (325 mg acetaminophen formulations)		
tramadol 50 mg tablet	FIORICET WITH CODEINE (butalbital/acetaminophen/codeine)	
tramadol/acetaminophen	hydrocodone/ibuprofen	
	levorphanol	
	meperidine	
	NALOCET (oxycodone/acetaminophen)	
	oxymorphone	
	pentazocine/naloxone	
	PERCOCET (oxycodone/acetaminophen)	
	PROLATE (oxycodone/acetaminophen)	
	ROXICODONE (oxycodone)	
	ROXYBOND (oxycodone)	
	tapentadol	
	tramadol 25 mg, 75 mg, 100 mg tablet	
	tramadol solution	
	XYVONA (levorphanol) ^{NR}	

ANALGESICS, OPIOID-LONG ACTING ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BUTRANS (buprenorphine)	BELBUCA (buprenorphine)	<p>Quantity Limit (per 31 rolling days)</p> <ul style="list-style-type: none"> • 31 tablets: AVINZA, hydromorphone ER, HYSINGLA ER, tramadol ER • 62 tablets: methadone, morphine ER, OXYCONTIN, oxymorphone ER, ZOHYDRO ER • 62 films: BELBUCA • 10 patches: fentanyl • 4 patches: BUTRANS <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 preferred agents in the past 6 months <p>Minimum Age Limit</p>
fentanyl patch	buprenorphine patch	
morphine sulfate ER tablet	CONZIP (tramadol)	
	DISKETS (methadone)	
	hydrocodone bitartrate ER	
	hydromorphone ER	
	HYSINGLA ER (hydrocodone)	
	methadone	
	methadone intensol	
	METHADOSE (methadone)	

	morphine sulfate ER capsule	<ul style="list-style-type: none"> • 18 years: BUTRANS
	MS CONTIN (morphine)	
	oxycodone ER	
	OXYCONTIN (oxycodone)	
	oxymorphone ER	
	tapentadol ER	
	tramadol ER	

ANALGESICS/ANESTHETICS (TOPICAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
diclofenac 3% gel	DERMACINRX LIDOCAINE (lidocaine)	<p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 1 bottle (112 mL): diclofenac 2% solution pump <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 preferred agents in the past 6 months <p>Lidocaine 5% Patch</p> <ul style="list-style-type: none"> • Documented diagnosis of Herpetic Neuralgia OR • Documented diagnosis of Diabetic Neuropathy <p>ZTLIDO</p> <ul style="list-style-type: none"> • Documented diagnosis of postherpetic neuralgia OR • History of 3 claims with preferred lidocaine 5% patch in the past 6 months
lidocaine 2% viscous solution	DERMACINRX LIDOCAN (lidocaine)	
lidocaine 4% cream, solution	DERMACINRX LIDOGEL (lidocaine)	
lidocaine 5% ointment, patch	DERMACINRX LIDOREX (lidocaine)	
	diclofenac epolamine	
lidocaine/prilocaine cream	diclofenac sodium 2% solution pump	
TRIDACAINE (lidocaine) patch	DICLOGEN (diclofenac/menthol/camphor) kit	
TRIDACAINE XL (lidocaine) patch	DOLOGESIC PAIN RELIEF (lidocaine)	
	LIDAFLEX (lidocaine)	
	lidocaine 3% cream	
	lidocaine 4% kit, liquid	
	lidocaine/hydrocortisone	
	lidocaine/prilocaine kit	
	LIDOCAN II, III, IV, V (lidocaine)	
	LIDOCORT (lidocaine/hydrocortisone)	
	LIDODERM (lidocaine)	
	LIDOTRAL (lidocaine)	
	LIXOFEN (diclofenac)	
	PLIAGLIS (lidocaine/tetracaine)	
	TRIDACAINE II, III (lidocaine) patch	
	ZTLIDO (lidocaine)	

ANDROGENIC AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
testosterone	ANDROGEL (testosterone)	<p>All Agents</p> <ul style="list-style-type: none"> • Limited to male gender <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
	JATENZO (testosterone undecanoate)	
	NATESTO (testosterone)	
	TESTIM (testosterone)	

	TLANDO (testosterone undecanoate)	TLANDO • Requires clinical review
	VOGELXO (testosterone)	
ANGIOTENSIN MODULATORS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS		<p>EPANED</p> <ul style="list-style-type: none"> Automatic approval issued for 0-6 years of age <p>valsartan/sacubitril</p> <ul style="list-style-type: none"> Age ≥1 year and documented diagnosis of Heart Failure with Systemic Ventricular Systolic Dysfunction OR Age ≥ 18 years and documented diagnosis of Heart Failure <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> ACEIs: <ul style="list-style-type: none"> Have tried 2 different preferred single entity agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ACEI Combinations: <ul style="list-style-type: none"> Have tried 2 different preferred ACEI combination agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ACEI/Diuretic Combinations: <ul style="list-style-type: none"> Have tried 2 different preferred ACEI/Diuretic agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ARBs: <ul style="list-style-type: none"> Have tried 2 different preferred single entity agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ARB Combinations: <ul style="list-style-type: none"> Have tried 1 preferred ARB combination agent in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ARB/Diuretic Combinations: <ul style="list-style-type: none"> Have tried 2 different preferred ARB/Diuretic agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days Direct Renin Inhibitors: <ul style="list-style-type: none"> Documented diagnosis of Hypertension AND Have tried 2 different preferred ACEI or ARB single-entity agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days Direct Renin Inhibitor Combinations: <ul style="list-style-type: none"> Documented diagnosis of Hypertension AND Have tried 2 different preferred ACEI or ARB diuretic agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days Have tried 2 different preferred ACEI/Diuretic agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days
ACE INHIBITOR (ACEI) COMBINATIONS		
benazepril/amlodipine	ACCURETIC (quinapril/hydrochlorothiazide)	
benazepril/hydrochlorothiazide	LOTENSIN HCT (benazepril/hydrochlorothiazide)	
captopril/hydrochlorothiazide	LOTREL (benazepril/amlodipine)	
enalapril/hydrochlorothiazide	ZESTORETIC (lisinopril/hydrochlorothiazide)	
fosinopril/hydrochlorothiazide		
lisinopril/hydrochlorothiazide		
quinapril/hydrochlorothiazide		
trandolapril/verapamil ER		
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)		
irbesartan	ARBLI (losartan)	
losartan	ATACAND (candesartan)	
olmesartan	AVAPRO (irbesartan)	
telmisartan	azilsartan	
valsartan tablet	BENICAR (olmesartan)	
	candesartan	
	COZAAR (losartan)	
	DIOVAN (valsartan)	
	EDARBI (azilsartan)	
	MICARDIS (telmisartan)	
	valsartan solution	
ARB COMBINATIONS		

irbesartan/hydrochlorothiazide	ATACAND HCT (candesartan/hydrochlorothiazide)	
losartan/hydrochlorothiazide	AVALIDE (irbesartan/hydrochlorothiazide)	
olmesartan/amlodipine	AZOR (olmesartan/hydrochlorothiazide)	
olmesartan/amlodipine/hydrochlorothiazide	BENICAR HCT (olmesartan/hydrochlorothiazide)	
olmesartan/hydrochlorothiazide	candesartan/hydrochlorothiazide	
telmisartan/hydrochlorothiazide	DIOVAN-HCT (valsartan/hydrochlorothiazide)	
valsartan/amlodipine	EDARBYCLOR (azilsartan/chlorthalidone)	
valsartan/hydrochlorothiazide	ENTRESTO (valsartan/sacubitril)	
valsartan/sacubitril ^{DUR+}	EXFORGE (valsartan/amlodipine)	
	EXFORGE HCT (valsartan/amlodipine/hydrochlorothiazide)	
	HYZAAR (losartan/hydrochlorothiazide)	
	MICARDIS HCT (telmisartan/hydrochlorothiazide)	
	telmisartan/amlodipine	
	TRIBENZOR (olmesartan/amlodipine/hydrochlorothiazide)	
	valsartan/amlodipine/hydrochlorothiazide	
	WIDAPLIK (telmisartan/amlodipine/indapamide)	
DIRECT RENIN INHIBITORS		
	aliskiren	
	TEKTURNA (aliskiren)	
ANTIBIOTICS (GI) & RELATED AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
metronidazole tablet	AEMCOLO (rifamycin)	
neomycin	DIFICID (fidaxomicin)	
tinidazole	FIRVANQ (vancomycin)	
vancomycin capsule, oral solution	FLAGYL (metronidazole)	

	LIKMEZ (metronidazole)
	metronidazole 125 mg tablet, 375 mg capsule
	nitazoxanide
	paromomycin
	REBYOTA (fecal microbiota, live-jslm)
	VANCOCIN (vancomycin)
	VOWST (fecal microbiota spore, live-brpk)

ANTIBIOTICS (MISCELLANEOUS)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LINCOSAMIDE ANTIBIOTICS		Quantity Limit • 6 tablets/month: SIVEXTRO SIVEXTRO MANUAL PA
clindamycin	CLEOCIN (clindamycin) CELOCIN PEDIATRIC (clindamycin)	
MACROLIDES		
azithromycin	E.E.S. (erythromycin ethylsuccinate) suspension	
clarithromycin	ERYPED (erythromycin ethylsuccinate) suspension	
clarithromycin ER	ERYTHROCIN (erythromycin stearate)	
E.E.S. (erythromycin ethylsuccinate) 400mg tablet	ZITHROMAX (azithromycin)	
ERY-TAB (erythromycin)		
erythromycin		
erythromycin ethylsuccinate		
NITROFURANTOIN DERIVATIVES		
nitrofurantoin capsule	FURADANTIN (nitrofurantoin) suspension	
nitrofurantoin monohydrate macrocrystals	MACROBID (nitrofurantoin monohydrate macrocrystals) nitrofurantoin suspension	
OXAZOLIDINONES		
linezolid tablet	linezolid suspension	
	SIVEXTRO (tedizolid)	
	ZYVOX (linezolid)	

ANTIBIOTICS (TOPICAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
bacitracin ^{OTC}	CENTANY (mupirocin)	
bacitracin/polymyxin ^{OTC}	CENTANY AT (mupirocin)	
gentamicin sulfate	mupirocin cream	
mupirocin ointment	XEPI (ozenoxacin)	
neomycin/bacitracin/polymyxin ^{OTC}		

ANTIBIOTICS (VAGINAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CLEOCIN (clindamycin)	clindamycin phosphate	
NUVESSA (metronidazole)	CLINDESSE (clindamycin)	
	SOLOSEC (secnidazole)	
	XACIATO (clindamycin)	

ANTICOAGULANTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LOW MOLECULAR WEIGHT HEPARIN (LMWH)		<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • LMWH: <ul style="list-style-type: none"> ○ Have tried 1 preferred agent in the past 6 months OR ○ 90 days of therapy with the requested agent in the past 105 days • Oral: <ul style="list-style-type: none"> ○ Have tried 2 different preferred oral agents in the past 6 months OR ○ 90 days of therapy with the requested agent in the past 105 days <p>XARELTO Dose Pack</p> <ul style="list-style-type: none"> • Requires clinical review
enoxaparin	ARIXTRA (fondaparinux)	
	fondaparinux	
	FRAGMIN (dalteparin)	
	LOVENOX (enoxaparin)	
ORAL		
dabigatran	PRADAXA (dabigatran)	
ELIQUIS (apixaban)	rivaroxaban	
ELIQUIS SPRINKLE (apixaban)	SAVAYSA (edoxaban)	
JANTOVEN (warfarin)	XARELTO (rivaroxaban) dose pack	
warfarin		
XARELTO (rivaroxaban) tablet, suspension		

ANTICONVULSANTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ADJUVANTS		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 6 months: DIACOMIT • 1 year: BANZEL, EPIDIOLEX • 2 years: ONFI, SYMPAZAN, SUBVENITE, VALTOCO • 12 years: NAYZILAM <p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 2 years: VIGAFYDE <p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 2 twin packs: DIASTAT • 2 packages: NAYZILAM • 5 blister packs: VALTOCO <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months OR • Documented diagnosis of Seizure AND • 90 days of therapy with the requested agent in the past 105 days <p>BANZEL, ONFI, and SYMPAZAN</p> <ul style="list-style-type: none"> • Documented diagnosis of Lennox-Gastaut Syndrome and have tried 1 preferred agent for Lennox-Gastaut Syndrome in the past 6 months OR • Documented diagnosis of Seizure AND 90 days of therapy with the requested agent in the past 105 days
carbamazepine	APTIOM (eslicarbazepine acetate)	
carbamazepine ER 12-hour capsule	BANZEL (rufinamide)	
DEPAKOTE ER (divalproex)	brivaracetam	
DEPAKOTE SPRINKLE (divalproex)	BRIVIACT (brivaracetam)	
divalproex	carbamazepine ER 12-hour tablet	
divalproex ER	CARBATROL (carbamazepine)	
divalproex sprinkle	DEPAKOTE (divalproex)	
EPIDIOLEX (cannabidiol)	DIACOMIT (stiripentol)	
lacosamide	ELEPSIA XR (levetiracetam)	
lamotrigine	EPRONTIA (topiramate)	
lamotrigine blue, green, orange dose pack	EQUETRO (carbamazepine)	
levetiracetam	eslicarbazepine	
levetiracetam ER	felbamate	
oxcarbazepine tablet	FELBATOL (felbamate)	
tiagabine	FINTEPLA (fenfluramine)	
topiramate	FYCOMPA (perampanel)	

topiramate sprinkle 15, 25 mg (generic Topamax)	KEPPRA (levetiracetam)	DIACOMIT • Documented diagnosis of Dravet Syndrome AND • 1 claim for clobazam in the past 30 days
TRILEPTAL (oxcarbazepine) suspension	KEPPRA XR (levetiracetam)	
valproic acid	LAMICTAL (lamotrigine)	EPIDIOLEX • Documented diagnosis of Dravet Syndrome, Lennox-Gastaut Syndrome, or Seizures associated with Tuberous Sclerosis Complex OR • 1 claim for EPIDIOLEX in the past 30 days
zonisamide	LAMICTAL XR (lamotrigine)	
	lamotrigine ER	FINTEPLA • Requires clinical review
	lamotrigine ODT	
	lamotrigine ODT blue, green, orange dose pack	SABRIL Powder for Oral Solution • Documented diagnosis of Infantile Spasms OR • Have tried 2 different preferred agents in the past 6 months OR • Documented diagnosis of Seizure AND • 90 days of therapy with the requested agent in the past 105 days
	MOTPOLY XR (lacosamide)	
	oxcarbazepine suspension	TOPIRAMATE ER • Documented diagnosis of Seizure AND • 90 days of therapy with the requested agent in the past 105 days OR • 30 days of therapy with topiramate IR in the past 6 months
	oxcarbazepine ER	
	OXTELLAR XR (oxcarbazepine)	VIGAFYDE • Age ≤ 2 years AND • Documented diagnosis of infantile spasms
	perampanel ^{NR}	
	QUDEXY XR (topiramate)	XCOPRI • Age ≥ 18 years
	ROWEEPRA (levetiracetam)	
	rufinamide	HYDANTOINS
	SABRIL (vigabatrin)	
	SPRITAM (levetiracetam)	DILANTIN (phenytoin)
	SUBVENITE (lamotrigine)	
	SUBVENITE (lamotrigine) blue, green, orange dose pack	DILANTIN-125 (phenytoin)
	TEGRETOL (carbamazepine)	
	TEGRETOL XR (carbamazepine)	
	TOPAMAX TABLET (topiramate)	
	TOPAMAX SPRINKLE (topiramate)	
	topiramate ER capsule (generic Trokendi XR)	
	topiramate ER sprinkle capsule (generic Qudexy XR)	
	topiramate sprinkle 50 mg	
	TRILEPTAL (oxcarbazepine) tablet	
	TROKENDI XR (topiramate)	
	vigabatrin	
	VIGADRONE (vigabatrin)	
	VIGAFYDE (vigabatrin)	
	VIGPODER (vigabatrin)	
	VIMPAT (lacosamide)	
	XCOPRI (cenobamate)	
	ZONISADE (zonisamide) suspension	
	ZTALMY (ganaxolone)	

PHENYTEK (phenytoin)	
phenytoin	
phenytoin ER	
SELECTED BENZODIAZEPINES	
clobazam	DIASTAT (diazepam) rectal gel
diazepam rectal gel	LIBERVANT (diazepam)
NAYZILAM (midazolam)	ONFI (clobazam)
VALTOCO (diazepam)	SYMPAZAN (clobazam)
SUCCINIMIDES	
ethosuximide	CELONTIN (methsuximide)
	methsuximide
	ZARONTIN (ethosuximide)

ANTIDEPRESSANTS, OTHER ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
bupropion	AUVELITY (bupropion/dextromethorphan)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: all agents <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months OR • Have tried 1 preferred agent and 1 SSRI in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days <p>AUVELITY</p> <ul style="list-style-type: none"> • Documented diagnosis of major depressive disorder AND • 90 days of therapy with the requested agent in the past 105 days <p>OR</p> <ul style="list-style-type: none"> • Have tried preferred bupropion for 60 days in the past 6 months AND • Have tried another preferred agent that is not bupropion for 60 days in the past 6 months • Indication of agitation associated with dementia due to Alzheimer's disease requires clinical review <p>DRIZALMA SPRINKLE</p> <ul style="list-style-type: none"> • Automatic approval issued with a diagnosis of Generalized Anxiety Disorder for 7-11 years of age <p>duloxetine 20 mg, 30 mg, 60 mg DR capsule</p> <ul style="list-style-type: none"> • Automatic approval issued with a diagnosis of Generalized Anxiety Disorder for 7-17 years of age <p>OR</p> <ul style="list-style-type: none"> • 90 days of therapy with the requested agent in the past 105 days <p>EXXUA</p> <ul style="list-style-type: none"> • Documented diagnosis of unipolar major depressive disorder AND • Have tried 2 different preferred agents in the past 6 months OR • Have tried 1 preferred agent and 1 SSRI in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days <p>RALDESY</p> <ul style="list-style-type: none"> • Requires clinical review <p>ZURZUVAE MANUAL PA</p>
bupropion SR	CYMBALTA (duloxetine)	
bupropion XL	desvenlafaxine ER	
duloxetine 20 mg, 30 mg, 60 mg DR capsule	DESYREL (trazodone)	
mirtazapine	DRIZALMA SPRINKLE (duloxetine DR)	
trazodone	duloxetine 40 mg DR capsule	
TRINTELLIX (vortioxetine)	EFFEXOR XR (venlafaxine)	
venlafaxine	EMSAM (selegiline)	
venlafaxine HCl ER	EXXUA (gepirone hcl)	
vilazodone	FETZIMA (levomilnacipran)	
	FORFIVO XL (bupropion)	
	MARPLAN (isocarboxazid)	
	NARDIL (phenelzine)	
	nefazodone	
	phenelzine	
	PRISTIQ (desvenlafaxine)	
	REMERON (mirtazapine)	
	tranylcypromine	
	Trazodone solution	
	venlafaxine besylate ER	
	VIIBRYD (vilazodone)	
	WELLBUTRIN SR (bupropion)	
	ZURZUVAE (zuranolone)	

ANTIDEPRESSANTS, SSRIs ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
citalopram solution, tablet	CELEXA (citalopram)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 6 years: ZOLOFT • 7 years: LEXAPRO, PROZAC • 8 years: fluvoxamine • 18 years: CELEXA, LUVOX CR, PAXIL, PROZAC 90 mg <p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 60 years CELEXA <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
escitalopram solution, tablet	citalopram capsule	
fluoxetine capsule, solution	escitalopram capsule	
fluvoxamine	fluoxetine tablet	
paroxetine tablet	fluoxetine DR capsule	
paroxetine CR	fluvoxamine ER capsule	
paroxetine ER	LEXAPRO (escitalopram)	
sertraline tablet, solution	paroxetine suspension, capsule	
	PAXIL (paroxetine)	
	PAXIL CR (paroxetine)	
	PROZAC (fluoxetine)	
	sertraline capsule	
	ZOLOFT (sertraline)	

ANTIEMETICS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
5HT3 RECEPTOR BLOCKERS		<p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 6 tablets: AKYNZEO • 100 mL: ZOFTRAN solution <p>Non-Preferred Agents</p> <ul style="list-style-type: none"> • Have tried 1 preferred agent in the past 6 months <p>AKYNZEO MANUAL PA</p> <p>GRANISOL, NEREUS</p> <ul style="list-style-type: none"> • Requires clinical review <p>Note: Injectables in this class are closed to point of sale. PA required if not administered in clinic/hospital.</p>
ondansetron solution, tablet	ANZIMET (dolasetron)	
ondansetron ODT 4 mg, 8 mg	granisetron	
	GRANISOL (granisetron)	
	ondansetron ODT 16 mg tablet	
	SANCUSO (granisetron)	
ANTIEMETIC COMBINATIONS		
DICLEGIS (doxylamine/pyridoxine)	AKYNZEO (netupitant/palonosetron)	
	BONJESTA (doxylamine/pyridoxine)	
	doxylamine/pyridoxine	
CANNABINOIDS		
	dronabinol	
	MARINOL (dronabinol)	
NMDA RECEPTOR ANTAGONISTS		
aprepitant	EMEND (aprepitant)	
	NEREUS (tradipitant) ^{NR}	

ANTIFUNGALS (ORAL) ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
clotrimazole	BREXAFEMME (ibrexafungerp)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: CRESEMBA <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months <p>HIV Opportunistic Infection</p> <ul style="list-style-type: none"> • Non-Preferred agent indicated for treatment (^) AND • Documented diagnosis of HIV
fluconazole	CRESEMBA (isavuconazonium sulfate)	
nystatin	DIFLUCAN (fluconazole)	
terbinafine	flucytosine [^]	
	FULVICIN P-G (griseofulvin ultramicrosize)	
	griseofulvin	

	griseofulvin ultramicrosized	CRESEMBA MANUAL PA griseofulvin suspension <ul style="list-style-type: none"> • Automatic approval issued for 0-11 years of age griseofulvin tablets (all except ultramicrodose 165 mg) <ul style="list-style-type: none"> • Automatic approval issued for 12-17 years of age FULVICIN P-G, griseofulvin ultramicrodose 165 mg tablets, SPORANOX <ul style="list-style-type: none"> • Requires clinical review
	itraconazole [^]	
	ketoconazole	
	NOXAFIL (posaconazole)	
	ORAVIG (miconazole)	
	posaconazole [^]	
	SPORANOX (itraconazole)	
	TOLSURA (itraconazole)	
	VFEND (voriconazole)	
	VIVJOA (oteseconazole)	
	voriconazole [^]	

ANTIFUNGALS (TOPICAL) ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIFUNGALS		Non-Preferred Criteria <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months LASOLEX, clotrimazole 30 mL solution <ul style="list-style-type: none"> • Require clinical review
ciclopirox cream, gel, solution, suspension	BENSAL HP (salicylic acid)	
clotrimazole cream, solution ^{Rx & OTC}	CILODAN (ciclopirox)	
econazole	ciclopirox shampoo	
ketoconazole cream, shampoo	clotrimazole solution (NDCs 50228-0502-61, 82568-0036-06)	
miconazole cream, powder, solution ^{OTC}	EXTINA (ketoconazole)	
nystatin cream, ointment, powder	ketoconazole foam	
terbinafine ^{OTC}	KETODAN (ketoconazole)	
tolnaftate cream, powder ^{OTC}	LASOLEX (clotrimazole) ^{OTC}	
tavaborole	LOPROX (ciclopirox)	
	luliconazole	
	miconazole/zinc oxide/petrolatum ointment	
	MICOTRIN AC (clotrimazole)	
	MICOTRIN AP (miconazole nitrate powder)	
	MYCOZYL AC (clotrimazole)	
	MYCOZYL AP (miconazole)	
	naftifine	
	NAFTIN (naftifine)	
	oxiconazole	
	OXISTAT (oxiconazole)	
	VOTRIZA-AL (clotrimazole)	
	VUSION (miconazole/zinc oxide/petrolatum)	
ANTIFUNGAL/STEROID COMBINATIONS		
clotrimazole/betamethasone cream	clotrimazole/betamethasone lotion	
nystatin/triamcinolone		

ANTIFUNGALS (VAGINAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
3-DAY VAGINAL CREAM (clotrimazole) ^{OTC}	GYNAZOLE 1 (butoconazole)	
clotrimazole cream ^{OTC}	miconazole 3 kit ^{OTC}	
clotrimazole-3 cream	terconazole suppository	
miconazole 1 ^{OTC}		
miconazole 3 combo pack ^{OTC} , cream ^{OTC} , suppository		
miconazole 7 ^{OTC}		
terconazole cream		

ANTIHISTAMINES, MINIMALLY SEDATING AND COMBINATIONS^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MINIMALLY SEDATING ANTIHISTAMINES		
cetirizine capsule, solution, tablet ^{OTC}	cetirizine chewable tablet ^{OTC}	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> Documented diagnosis of Allergy or Urticaria AND Have tried 2 different preferred agents in the past 12 months <p>Quantity Limit</p> <ul style="list-style-type: none"> 118 mL: desloratadine solution <p>DES Loratadine Solution</p> <ul style="list-style-type: none"> Requires clinical review
loratadine chewable tablet, ODT, solution, tablet ^{OTC}	CLARINEX (desloratadine)	
	desloratadine	
	levocetirizine	
MINIMALLY SEDATING ANTIHISTAMINE/DECONGESTANT COMBINATIONS		
cetirizine/pseudoephedrine	CLARINEX-D 12 HOUR (desloratadine/pseudoephedrine)	
loratadine/pseudoephedrine ^{OTC}		

ANTIMIGRAINE AGENTS, ACUTE TREATMENT

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CGRP ORAL AND NASAL		
NURTEC ODT (rimegepant)	ZAVZPRET (zavegepant)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> 6 years: MAXALT 12 years: almotriptan, sumatriptan/naproxen, ZOMIG nasal spray 18 years: FROVA, IMITREX, naratriptan, NURTEC ODT, RELPAX, REYVOW, SYMBRAVO, TOSYMRA, UBRELVY, ZEMBRACE, ZOMIG tablets <p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> ORAL <ul style="list-style-type: none"> 4 tablets: REYVOW 50 mg 6 tablets: almotriptan, RELPAX, ZOMIG 8 tablets: NURTEC ODT, REYVOW 100 mg 9 tablets: naratriptan, FROVA, IMITREX, sumatriptan/naproxen, SYMBRAVO 12 tablets: MAXALT 16 tablets: UBRELVY NASAL <ul style="list-style-type: none"> 1 box: all agents <p>CUMULATIVE Quantity Limit (per 31 days)</p>
UBRELVY (ubrogepant)		
INJECTABLES		
sumatriptan pen injector, vial	IMITREX (sumatriptan)	
	sumatriptan cartridge	
	ZEMBRACE SYMTOUCH (sumatriptan)	
NASAL		
sumatriptan spray	IMITREX (sumatriptan)	
zolmitriptan spray	TOSYMRA (sumatriptan)	
	ZOMIG (zolmitriptan)	
TRIPHTANS AND RELATED AGENTS (ORAL)^{DUR+}		
naratriptan	almotriptan	

rizatriptan	eletriptan	<ul style="list-style-type: none"> • INJECTABLES <ul style="list-style-type: none"> ○ 4 injections: all agents • Non-Preferred Criteria • ORAL <ul style="list-style-type: none"> ○ Have tried 2 preferred oral agents in the past 90 days • NASAL <ul style="list-style-type: none"> ○ Requires clinical review • INJECTABLES <ul style="list-style-type: none"> ○ Requires clinical review • Almotriptan and sumatriptan/naproxen <ul style="list-style-type: none"> • Automatic approval for 12-17 years of age • NURTEC ODT and UBRELVY MANUAL PA <ul style="list-style-type: none"> • Documented diagnosis of Migraine AND • Have tried 2 different triptans in the past 6 months AND • No concurrent therapy with another CGRP agent or strong CYP3A4 inhibitor • REYVOW <ul style="list-style-type: none"> • Documented diagnosis of Migraine AND • Have tried 2 different triptans in the past 90 days AND • Have tried preferred NURTEC ODT in the past 90 days • SYMBRAVO <ul style="list-style-type: none"> • Requires clinical review • ZAVZPRET MANUAL PA <ul style="list-style-type: none"> • Documented diagnosis of Migraine AND • Have tried 2 different triptans in the past 6 months AND • Have tried both NURTEC ODT and UBRELVY in the past 6 months AND • No concurrent therapy with another CGRP AGENT
sumatriptan	FROVA (frovatriptan)	
zolmitriptan	frovatriptan	
zolmitriptan ODT	IMITREX (sumatriptan)	
	MAXALT (rizatriptan)	
	MAXALT MLT (rizatriptan)	
	RELPAX (eletriptan)	
	REYVOW (lasmiditan)	
	sumatriptan/naproxen	
	SYMBRAVO (rizatriptan benzoate/meloxicam)	
	ZOMIG (zolmitriptan)	

ANTIMIGRAINE AGENTS, PROPHYLAXIS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
INJECTABLES		<ul style="list-style-type: none"> • Preferred Injectables <ul style="list-style-type: none"> • History of 3 claims with the requested agent in the past 105 days OR • New starts require manual PA (see criteria below) • AJOVY Autoinjector 3 Pack requires clinical review • Non-preferred Injectables <ul style="list-style-type: none"> • Requires clinical review • Quantity Limit <ul style="list-style-type: none"> • 4.5 mL (per 90 days): AJOVY Autoinjector 3 Pack • AIMOVIG, AJOVY (except Autoinjector 3 Pack), EMGALITY, NURTEC ODT, and QULIPTA MANUAL PA • VYEPTI MANUAL PA
AIMOVIG Autoinjector (erenumab-aooe) ^{DUR+}	EMGALITY Syringe (galcanezumab-gnlm) 300 mg/mL	
AJOVY Autoinjector (fremanezumab-vfrm) ^{DUR+}	VYEPTI (eptinezumab-jjmr)	
AJOVY Syringe (fremanezumab-vfrm) ^{DUR+}		
EMGALITY Pen (galcanezumab-gnlm) ^{DUR+}		
EMGALITY Syringe (galcanezumab-gnlm) 120 mg/mL ^{DUR+}		
ORAL		
	QULIPTA (atogepant)	
	NURTEC ODT (rimegepant)	

ANTINEOPLASTICS SELECTED SYSTEMIC ENZYME INHIBITORS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BOSULIF (bosutinib) tablet	AFINITOR (everolimus)	LYNPARZA Tablets MANUAL PA
CAPRESLA (vandetanib)	AFINITOR DISPERZ (everolimus)	
COMETRIQ (cabozantinib)	AKEEGA (niraparib/abiraterone)	
COTELLIC (cobimetinib)	ALECENSA (alectinib)	
everolimus	ALUNBRIG (brigatinib)	
GILOTRIF (afatinib)	AUGTYRO (repotrectinib)	
IBTROZI (taletrectinib)	AYVAKIT (avapritinib)	
ICLUSIG (ponatinib)	BALVERSA (erdafitinib)	
imatinib	BOSULIF (bosutinib) capsule	
IMBRUVICA (ibrutinib)	BRAFTOVI (encorafenib)	
INLYTA (axitinib)	BRUKINSA (zanubrutinib)	
IRESSA (gefitinib)	CABOMETYX (cabozantinib)	
JAKAFI (ruxolitinib)	CALQUENCE (acalabrutinib)	
JAKAFI XR (ruxolitinib)		
MEKINIST (trametinib)	COPIKTRA (duvelisib)	
NEXAVAR (sorafenib)	DANZITEN (nilotinib)	
ROZLYTREK (entrectinib)	dasatinib	
SPRYCEL (dasatinib)	DAURISMO (glasdegib)	
STIVARGA (regorafenib)	ENSACOVE (ensartinib hydrochloride) ^{NR}	
SUTENT (sunitinib)	ERIVEDGE (vismodegib)	
TAFINLAR (dabrafenib)	ERLEADA (apalutamide)	
TARCEVA (erlotinib)	erlotinib	
TASIGNA (nilotinib)	FOTIVDA (tivozanib)	
TURALIO (pexidartinib)	FRUZAQIA (fruquintinib)	
TYKERB (lapatinib)	GAVRETO (pralsetinib)	
VOTRIENT (pazopanib)	gefitinib	
XALKORI (crizotinib)	GLEEVEC (imatinib)	
XTANDI (enzalutamide)	HERNEXEOS (zongertinib)	
ZELBORAF (vemurafenib)	HYRNUO (sevabertinib)	
ZYDELIG (idelalisib)	IBRANCE (palbociclib)	
ZYKADIA (ceritinib)	IDHIFA (enasidenib)	
	IMKELDI (imatinib)	
	INLURIYO (imlunestrant tosylate)	
	INQOVI (decitabine/cedazuridine)	
	INREBIC (fedratinib)	
	ITOVEBI (inavolisib)	
	IWILFIN (eflornithine)	
	JAYPIRCA (pirtobrutinib)	
	KISQALI (ribociclib)	
	KISQALI-FEMARA CO-PACK (ribociclib/letrozole)	
	KOMZIFTI (ziftomenib) ^{NR}	

	KOSELUGO (selumetinib sulfate)
	KRAZATI (adagrasib)
	lapatinib
	LAZCLUZE (lazertinib)
	LENVIMA (lenvatinib)
	LIFYORLI (relacorilant) ^{NR}
	LOBRENA (lorlatinib)
	LUMAKRAS (sotorasib)
	LYNPARZA (olaparib)
	LYTGOBI (futibatinib)
	MEKTOVI (binimetinib)
	MODEYSO (dordaviprone)
	NERLYNX (neratinib)
	nilotinib
	NUBEQA (darolutamide)
	ODOMZO (sonidegib)
	OGSIVEO (nirogacestat)
	OJEMDA (tovorafenib)
	OJJAARA (momelotinib)
	ONUREG (azacitidine)
	ORGOVYX (relugolix)
	ORSERDU (elacestrant)
	pazopanib
	PEMAZYRE (pemigatinib)
	PIQRAY (alpelisib)
	QINLOCK (ripretinib)
	RETEVMO (selpercatinib)
	REVUFORJ (revumenib)
	REZLIDHIA (olutasidenib)
	RUBRACA (rucaparib)
	RYDAPT (midostaurin)
	SCSEMBLIX (asciminib)
	sorafenib
	sunitinib
	TABRECTA (capmatinib)
	TAGRISSO (osimertinib)
	TALZENNA (talazoparib)
	TAZVERIK (tazemetostat)
	TEPMETKO (tepotinib)
	TIBSOVO (ivosidenib)
	TORPENZ (everolimus)
	TRUQAP (capiwasertib)
	TUKYSA (tucatinib)
	VANFLYTA (quizartinib)
	VERZENIO (abemaciclib)
	VITRAKVI (larotrectinib)
	VIZIMPRO (dacomitinib)
	VONJO (pacritinib)
	VORANIGO (vorasidenib)
	WELIREG (belzutifan)
	XOSPATA (gilteritinib)
	XPOVIO (selinexor)
	ZEJULA (niraparib)

ANTIOBESITY SELECT AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SAXENDA (liraglutide)	liraglutide	All agents MANUAL PA required WEGOVY • Submission of a manual PA and clinical review may be required when DUR+ electronic PA criteria are not met. • Reauthorization after 12 months requires submission of a manual PA to confirm continued appropriateness of therapy.
WEGOVY (semaglutide) ^{DUR+}	orlistat	
	XENICAL (orlistat)	
ANTIPARASITICS (TOPICAL) ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PEDICULICIDES		Minimum Age Limit • 2 months: permethrin 1% (OTC), permethrin 5% • 6 months: NATROBA, SKLICE • 2 years: piperonyl/pyrethrins (OTC) • 4 years: NATROBA • 6 years: OVIDE • 18 years: EURAX Non-Preferred Criteria • Pediculicides ○ Have tried 2 preferred topical lice agents in the past 90 days • Scabicides ○ Have tried permethrin 5% in the past 90 days
permethrin 1% cream ^{OTC}	lindane	
spinosad	NATROBA (spinosad)	
VANALICE (piperonyl butoxide/pyrethrins)	malathion	
	OVIDE (malathion)	
	SKLICE (ivermectin)	
SCABICIDES		
ivermectin	CROTAN (crotamiton)	
permethrin 5% cream	ELIMITE (permethrin)	
	EURAX (crotamiton)	
	STROMECTOL (ivermectin)	
ANTIPARKINSON'S AGENTS (INJECTABLE)		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	VYALEV (foscarbidopa/foslevodopa)	VYALEV • Requires clinical review
ANTIPARKINSON'S AGENTS (ORAL) ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTICHOLINERGICS		Non-Preferred Criteria • Documented diagnosis of Parkinson's disease AND • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with a selegiline agent in the past 105 days GOCOVRI • Documented diagnosis of Parkinson's disease AND • 30 days of therapy with amantadine IR in the past 105 days AND • 30 days of therapy with a carbidopa/levodopa combination agent in the past 45 days INBRIJA • Documented diagnosis of Parkinson's disease AND • 30 days of therapy with a carbidopa/levodopa combination agent in the past 45 days NOURIANZ • Documented diagnosis of Parkinson's Disease AND • Have tried 1 preferred carbidopa/levodopa combination agent in the past 30 days AND • 30 days of therapy with a preferred adjunctive therapy in the past 45 days
benztropine		
trihexyphenidyl		
COMT INHIBITORS		
entacapone	OAGENTYS (opicapone)	
DOPAMINE AGONISTS		
pramipexole	NEUPRO (rotigotine)	
ropinirole	pramipexole ER	
	ropinirole ER	
MAO-B INHIBITORS		
selegiline	AZILECT (rasagiline)	
	rasagiline	
	XADAGO (safinamide)	
OTHERS		
amantadine	bromocriptine capsule	
bromocriptine tablet	carbidopa	

carbidopa/levodopa ER tablet	carbidopa/levodopa ER capsule	XADAGO <ul style="list-style-type: none"> Documented diagnosis of Parkinson's Disease AND History of 30 days of therapy with a carbidopa/levodopa combination agent in the past 45 days AND History of 30 days of therapy with a selegiline agent the in past 45 days
carbidopa/levodopa tablet	carbidopa/levodopa ODT	
	carbidopa/levodopa/entacapone	
	CREXONT (carbidopa/levodopa)	
	DHIVY (carbidopa/levodopa)	
	DUOPA (carbidopa/levodopa)	
	GOCOVRI (amantadine)	
	INBRIJA (levodopa)	
	NOURIANZ (istradefylline)	
	OSMOLEX ER (amantadine)	
	RYTARY (carbidopa/levodopa)	
	SINEMET (carbidopa/levodopa)	
	STALEVO (carbidopa/levodopa/entacapone)	

ANTIPSORIATICS (TOPICAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcipotriene cream	calcipotriene foam, ointment, solution	
ENSTILAR (calcipotriene/betamethasone)	calcipotriene/betamethasone	
TACLONEX (calcipotriene/betamethasone)	calcitriol ointment	
	SORILUX (calcipotriene)	
	tazarotene	
	VECTICAL (calcitriol)	
	VTAMA (tapinarof)	
	ZORYVE (roflumilast)	

ANTIPSYCHOTICS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
INJECTABLE, ATYPICALS ^{DUR+}		Concurrent Therapy Limit for Age < 18 years <ul style="list-style-type: none"> 90 days with ≥ 2 agents in the last 120 days will require a MANUAL PA Minimum Age Limit <ul style="list-style-type: none"> 3 years: HALDOL 5 years: RISPERDAL, thioridazine 6 years: ABILIFY, trifluoperazine 10 years: LATUDA, SAPHRIS, SEROQUEL, SYMBYAX, VRAYLAR (0.5, 0.75, 1.5, 3, 4.5 mg) 12 years: INVEGA, molindone, perphenazine, pimozide, thiothixene 13 years: REXULTI, ZYPREXA 18 years: ABILIFY MYCITE, CAPLYTA, CLOZARIL, COBENFY, FANAPT, fluphenazine, GEODON, loxapine, LYBALVI, NUPLAZID, perphenazine/amitriptyline, SECUADO, VRAYLAR 6 mg, and all injectable agents
ABILIFY ASIMTUFII (aripiprazole)	ERZOFRI (paliperidone palmitate)	
ABILIFY MAINTENA (aripiprazole)	GEODON (ziprasidone)	
ARISTADA, ARISTADA INITIO (aripiprazole lauroxil)	olanzapine	
INVEGA HAFYERA (paliperidone)	risperidone ER	
INVEGA SUSTENNA (paliperidone palmitate)	RYKINDO (risperidone)	

INVEGA TRINZA (paliperidone)	ziprasidone	<p>Quantity Limit</p> <ul style="list-style-type: none"> • 3 syringes/year: ARISTADA INITIO <p>Non-Preferred Criteria Oral Atypical Agents (unless specified below)</p> <ul style="list-style-type: none"> • Have tried 2 preferred agents in the past 12 months OR • 30 days of therapy with the requested agent in the past 180 days <p>ARISTADA INTIO, ARISTADA ER, INVEGA SUSTENNA, INVEGA TRINZA and PERSERIS</p> <ul style="list-style-type: none"> • Documented diagnosis of schizophrenia or schizoaffective disorder <p>ABILIFY MAINTENA, ABILIFY ASIMTUFII, RISPERDAL CONSTA, or UZEDY</p> <ul style="list-style-type: none"> • Documented diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder <p>CAPLYTA</p> <ul style="list-style-type: none"> • 30 days of therapy with the requested agent in the past 105 days OR • Documented diagnosis of Bipolar II Depression OR • Documented diagnosis of Bipolar I Depression AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days OR • Documented diagnosis of Major Depressive Disorder AND • 120 days of therapy with two antidepressants that are not atypical antipsychotics in the past 180 days AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days OR • Documented diagnosis of schizophrenia AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days <p>INVEGA HAFYERA</p> <ul style="list-style-type: none"> • Documented diagnosis of schizophrenia or schizoaffective disorder AND <ul style="list-style-type: none"> ○ 4 claims for INVEGA SUSTENNA in the past year OR ○ 1 claim for INVEGA TRINZA in the past year OR ○ 1 claim for INVEGA HAFYERA in the past year <p>ERZOFRI, generic risperidone ER, RYKINDO ER, and ZYPREXA RELPREV</p> <ul style="list-style-type: none"> • Require clinical review <p>NUPLAZID</p> <ul style="list-style-type: none"> • Documented diagnosis of Parkinson's Disease <p>VRAYLAR</p> <ul style="list-style-type: none"> • 30 days of therapy with the requested agent in the past 105 days OR • Age 10-17 years or older AND • Documented diagnosis of bipolar 1 disorder AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days OR • Age 13-17 years or older AND • Documented diagnosis of schizophrenia or schizoaffective disorder AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days OR • Age 18 years or older AND • Documented diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days OR
PERSERIS (risperidone)	ZYPREXA (olanzapine)	
RISPERDAL CONSTA (risperidone)	ZYPREXA RELPREV (olanzapine)	
UZEDY (risperidone)		
ORAL^{DUR+}		
aripiprazole tablet	ABILIFY (aripiprazole)	
asenapine	ABILIFY MYCITE (aripiprazole)	
clozapine tablet	ADASUVE (loxapine)	
fluphenazine	aripiprazole ODT, solution	
haloperidol	BYSANTI (milsaperidone) ^{NR}	
haloperidol lactate	CAPLYTA (lumateperone)	
lurasidone	chlorpromazine	
olanzapine	clozapine ODT	
perphenazine	CLOZARIL (clozapine)	
perphenazine/amitriptyline	COBENFY (xanomeline/trospium)	
quetiapine	FANAPT (iloperidone)	
quetiapine ER	GEODON (ziprasidone)	
risperidone	IGALMI (dexmedetomidine)	
thioridazine	INVEGA (paliperidone)	
trifluoperazine	LATUDA (lurasidone)	
ziprasidone	LYBALVI (olanzapine/samidorphane)	
	molindone	
	NUPLAZID (pimavanserin)	
	olanzapine/fluoxetine	
	OPIPZA (aripiprazole)	
	paliperidone ER	
	REXULTI (brexpiprazole)	
	RISPERDAL (risperidone)	
	SAPHRIS (asenapine)	
	SEROQUEL (quetiapine)	
	SEROQUEL XR (quetiapine ER)	
	SYMBYAX (olanzapine/fluoxetine)	
	VERSACLOZ (clozapine)	
	VRAYLAR (cariprazine)	
	ZYPREXA, ZYPREXA ZYDIS (olanzapine)	
TRANSDERMAL, ATYPICALS		
	SECUADO (asenapine)	

		<ul style="list-style-type: none"> • Age 18 years or older AND • Documented diagnosis of major depressive disorder AND • 120 days of therapy with two antidepressants that are not atypical antipsychotics in the past 180 days AND • 30 days of therapy with a preferred oral atypical antipsychotic indicated for requested diagnosis in the past 105 days <p>ARIPIRAZOLE ODT, CLOZAPINE ODT and OIPIZA</p> <ul style="list-style-type: none"> • Require clinical review
ANTIRETROVIRALS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CAPSID INHIBITORS		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 10 years: YEZTUGO <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • 1 claim with the requested agent in the past 105 days <p>STRIBILD MANUAL PA</p> <p>SUNLENCA</p> <ul style="list-style-type: none"> • Requires clinical review <p>TROGARZO</p> <ul style="list-style-type: none"> • Requires clinical review <p>TYBOST MANUAL PA</p> <p>NOTE: Agents with ** are indicated for Pre-Exposure Prophylaxis (PrEP).</p>
YEZTUGO** (lenacapavir) tablet and injection	SUNLENCA (lenacapavir)	
CD4 DIRECTED ATTACHMENT INHIBITORS		
	RUKOBIA (fostemsavir)	
CD4 DIRECTED HIV-1 INHIBITORS		
	TROGARZO (ibalizumab-uiyk)	
COMBINATION PRODUCTS NRTIs		
abacavir/lamivudine	COMBIVIR (lamivudine/zidovudine)	
CABENUVA (cabotegravir/rilpivirine)	EPZICOM (abacavir/lamivudine)	
DOVATO (dolutegravir/lamivudine)		
lamivudine/zidovudine		
COMBINATION PRODUCTS NUCLEOSIDE AND NUCLEOTIDE ANALOG RTIs		
DESCOVY** (emtricitabine/tenofovir alafenamide)	TRUVADA** (emtricitabine/tenofovir)	
emtricitabine/tenofovir**		
COMBINATION PRODUCTS NUCLEOSIDE AND NUCLEOTIDE ANALOG AND NON-NUCLEOSIDE RTIs		
DELSTRIGO (doravirine/lamivudine/tenofovir)	ATRIPLA (efavirenz/emtricitabine/tenofovir)	
efavirenz/emtricitabine/tenofovir	CIMDUO (lamivudine/tenofovir)	
ODEFSEY (emtricitabine/rilpivirine/tenofovir)	COMPLERA (emtricitabine/rilpivirine/tenofovir)	
	IDVYNSO (doravirine/islatravir) ^{NR}	
COMBINATION PRODUCTS PROTEASE INHIBITORS		
lopinavir/ritonavir	KALETRA (lopinavir/ritonavir)	

ENTRY INHIBITORS CCR5 CO-RECEPTOR ANTAGONISTS	
	maraviroc
	SELZENTRY (maraviroc)
ENTRY INHIBITORS FUSION INHIBITORS	
	FUZEON (enfuvirtide)
INTEGRASE STRAND TRANSFER INHIBITORS	
APREUDE** (cabotegravir)	cabotegravir ER
ISENTRESS (raltegravir)	ISENTRESS HD (raltegravir)
TIVICAY, TIVICAY PD (dolutegravir)	VOCABRIA (cabotegravir)
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI)	
EDURANT (rilpivirine)	etravirine
efavirenz	INTELENCE (etravirine)
	nevirapine, nevirapine ER
	PIFELTRO (doravirine)
	rilpivirine ^{NR}
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)	
abacavir	didanosine
EMTRIVA (emtricitabine)	emtricitabine
lamivudine	EPIVIR (lamivudine)
ZIAGEN (abacavir)	RETROVIR (zidovudine)
zidovudine	stavudine
	VIREAD (tenofovir disoproxil fumarate)
PHARMACOENHANCER CYTOCHROME P450 INHIBITORS	
	TYBOST (cobicistat)
PROTEASE INHIBITORS (NON-PEPTIDIC)	
darunavir	APTIVUS (tipranavir)
PREZISTA (darunavir) 75mg tablet, 150mg tablet, 100mg/mL suspension	PREZCOBIX (darunavir/cobicistat)
	PREZISTA (darunavir) 600mg tablet, 800mg tablet
PROTEASE INHIBITORS (PEPTIDIC)	
atazanavir	fosamprenavir
EVOTAZ (atazanavir/cobicistat)	LEXIVA (fosamprenavir)
ritonavir	NORIVIR (ritonavir)
	REYATAZ (atazanavir)
	VIRACEPT (nelfinavir)
SINGLE PRODUCT REGIMENS	
BIKTARVY (bictegravir/emtricitabine/te nofovir)	efavirenz/lamivudine/tenofovir

GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)	JULUCA (dolutegravir/rilpivirine)	
SYMFI (efavirenz/lamivudine/tenofovir)	rilpivirine ER	
SYMFI LO (efavirenz/lamivudine/tenofovir)	STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)	
TRIUMEQ (abacavir/dolutegravir/lamivudine)	SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	
TRIUMEQ PD (abacavir/dolutegravir/lamivudine)		
ANTIVIRALS, ORAL		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTI-CYTOMEGALOVIRUS AGENTS		PREVYMIS <ul style="list-style-type: none"> Requires clinical review Valganciclovir solution <ul style="list-style-type: none"> Automatic approval issued for 0-12 years of age
valganciclovir tablet	LIVTENCITY (maribavir)	
	PREVYMIS (letermovir)	
	VALCYTE (valganciclovir)	
	valganciclovir solution	
ANTI-HERPETIC AGENTS		
acyclovir	SITAVIG (acyclovir)	
famciclovir	VALTREX (valacyclovir)	
valacyclovir		
ANTI-INFLUENZA AGENTS		
oseltamivir	FLUMADINE (rimantadine)	
	RAPIVAB (peramivir)	
	RELENZA (zanamivir)	
	rimantadine	
	TAMIFLU (oseltamivir)	
	XOFLUZA (baloxavir)	
COVID-19		
PAXLOVID (nirmatrelvir/ritonavir)		
ANTIVIRALS, TOPICAL		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
acyclovir cream, ointment	DENAVIR (penciclovir)	ZELSUVM MANUAL PA
	penciclovir	
	ZELSUVM (berdazimer)	
AROMATASE INHIBITORS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
anastrozole	ARIMIDEX (anastrozole)	
exemestane	AROMASIN (exemestane)	
letrozole	FEMARA (letrozole)	

ATOPIC DERMATITIS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SYSTEMIC		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 3 months: EUCRISA • 2 years: OPZELURA, pimecrolimus, tacrolimus 0.03% • 16 years: tacrolimus 0.1% <p>ADBRY MANUAL PA</p> <p>ANZUPGO</p> <ul style="list-style-type: none"> • Requires clinical review <p>CIBINQO</p> <ul style="list-style-type: none"> • Requires clinical review <p>DUPIXENT</p> <ul style="list-style-type: none"> • 1 claim with DUPIXENT in the past 60 days OR • New starts require clinical review (see manual PA links below) <ul style="list-style-type: none"> ○ Allergic Fungal Rhinosinusitis MANUAL PA ○ Asthma MANUAL PA ○ Atopic Dermatitis MANUAL PA ○ Bullous Pemphigoid MANUAL PA ○ COPD MANUAL PA ○ Chronic Spontaneous Urticaria MANUAL PA ○ Eosinophilic Esophagitis MANUAL PA ○ Nasal Polyposis MANUAL PA ○ Prurigo Nodularis MANUAL PA <p>EBGLYSS MANUAL PA</p> <p>EUCRISA</p> <ul style="list-style-type: none"> • 30 days of therapy with a calcineurin inhibitor or topical steroid in the past 6 months <p>NEMLUVIO</p> <ul style="list-style-type: none"> • Atopic Dermatitis MANUAL PA • Prurigo Nodularis MANUAL PA <p>OPZELURA</p> <ul style="list-style-type: none"> • 30 days of therapy with pimecrolimus, EUCRISA or tacrolimus in the past 6 months
ADBRY (tralokinumab-ldrm)	CIBINQO (abrocitinib)	
ADBRY Autoinjector (tralokinumab-ldrm)	NEMLUVIO (nemolizumab-ilto)	
DUPIXENT (dupilumab) DUR+		
EBGLYSS pen and syringe (lebrikizumab-lbkz)		
TOPICAL		
EUCRISA (crisaborole) DUR+	ANZUPGO (delgocitinib)	
pimecrolimus	OPZELURA (ruxolitinib)	
tacrolimus	ZORYVE (roflumilast) 0.15% cream	

BETA BLOCKERS, ANTIANGINALS & SINUS NODE AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIANGINALS		<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
ranolazine ER	ASPRUZYO SPRINKLE (ranolazine)	
	RANEXA (ranolazine ER)	
BETA- AND ALPHA-BLOCKERS		<p>ASPRUZYO SPRINKLE, LOPRESSOR SOLUTION, and metoprolol tartrate 12.5 mg tablet</p> <ul style="list-style-type: none"> • Requires clinical review <p>COREG CR</p>
carvedilol	carvedilol ER	
labetalol	COREG (carvedilol)	
	COREG CR (carvedilol)	

BETA-BLOCKER/DIURETIC COMBINATIONS		<ul style="list-style-type: none"> • Documented diagnosis of hypertension AND • Have tried generic carvedilol AND 1 preferred agent in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days <p>CORLANOR MANUAL PA</p> <p>HEMANGEOL</p> <ul style="list-style-type: none"> • Documented diagnosis of infantile hemangioma
atenolol/chlorthalidone	TENORETIC (atenolol/chlorthalidone)	
bisoprolol/hydrochlorothiazide	ZIAC (bisoprolol/hydrochlorothiazide)	
metoprolol/hydrochlorothiazide		
propranolol/hydrochlorothiazide		
BETA-BLOCKERS		
acebutolol	BETAPACE (sotalol)	
atenolol	BETAPACE AF (sotalol)	
bisoprolol	betaxolol	
HEMANGEOL (propranolol)	BYSTOLIC (nebivolol)	
metoprolol succinate	INDERAL LA (propranolol)	
metoprolol tartrate (except 12.5 mg tablet)	INDERAL XL (propranolol)	
nadolol	INNOPRAN XL (propranolol)	
nebivolol	KAPSPARGO SPRINKLE (metoprolol succinate)	
pindolol	LOPRESSOR (metoprolol tartrate)	
propranolol	metoprolol tartrate 12.5 mg tablet	
propranolol ER	SOTYLIZE (sotalol)	
SORINE (sotalol)	TENORMIN (atenolol)	
sotalol	TOPROL XL (metoprolol succinate)	
sotalol AF		
timolol		
SINUS NODE AGENTS		
	CORLANOR (ivabradine)	
	ivabradine	
BILE SALTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ursodiol	BYLVAY (odevixibat)	
	CHENODAL (chenodiol)	
	IQIRVO (elafibranor)	
	LIVDELZI (seladelpar)	
	LIVMARLI (maralixibat)	
	OCALIVA (obeticholic acid)	
	RELTONE (ursodiol)	
	URSO FORTE (ursodiol)	
BLADDER RELAXANT PREPARATIONS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MYRBETRIQ (mirabegron)	darifenacin ER	Non-Preferred Criteria
oxybutynin	DETROL (tolterodine)	

oxybutynin ER	DETROL LA (tolterodine)	<ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
solifenacin	fesoterodine	
	GEMTESA (vibegron)	
	mirabegron ER	
	tolterodine	
	tolterodine ER	
	TOVIAZ (fesoterodine)	
	trospium	
	trospium ER	
	VESICARE (solifenacin)	
	VESICARE LS (solifenacin)	

BONE RESORPTION SUPPRESSION AND RELATED AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BISPHOSPHONATES ^{DUR+}		
alendronate tablet	ACTONEL (risedronate)	<p>Non-Preferred Bisphosphonate Criteria</p> <ul style="list-style-type: none"> • Documented diagnosis of osteoporosis or osteopenia AND • Have tried 2 different preferred agents in the past 6 months <p>Non-Preferred Others</p> <ul style="list-style-type: none"> • Requires clinical review
ibandronate tablet	alendronate solution	
risedronate	ATELVIA (risedronate)	
	BINOSTO (alendronate)	
	FOSAMAX (alendronate)	
	FOSAMAX PLUS D (alendronate/vitamin D3)	
	ibandronate syringe/vial	
	risedronate DR	
OTHERS		
BILDYOS (denosumab-nxxp)	AUKELSO (denosumab-kyqq)	
BILPREVDA (denosumab-nxxp)	BOMYNTRA (denosumab-bnht)	
FORTEO (teriparatide)	BONSITY (teriparatide)	
raloxifene	BOSAYA (denosumab-kyqq)	
	calcitonin salmon	
	CONEXXENCE (denosumab-bnht)	
	ENOBY (denosumab-qbde) ^{NR}	
	EVENITY (romosozumab-aqqg)	
	EVISTA (raloxifene)	
	JUBBONTI (denosumab-bbdz)	
	MIACALCIN (calcitonin salmon)	
	OSENVELT (denosumab-bmwo)	
	PROLIA (denosumab)	
	STOBOCLO (denosumab-bmwo)	
	teriparatide	
	TYMLOS (abaloparatide)	
	WYOST (denosumab-bbdz)	
	XGEVA (denosumab)	

	XTRENBO (denosumab-qbde) ^{NR}	
BPH AGENTS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
5-ALPHA-REDUCTASE INHIBITORS		<p>CARDURA, FLOMAX, PROSCAR, terazosin, or UROXATRAL Female</p> <ul style="list-style-type: none"> Documented State-accepted diagnosis <p>Non-Preferred Criteria Male</p> <ul style="list-style-type: none"> Have tried 2 different preferred agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days <p>ENTADFI</p> <ul style="list-style-type: none"> Requires clinical review
dutasteride	AVODART (dutasteride)	
finasteride	ENTADFI (finasteride/tadalafil)	
	PROSCAR (finasteride)	
ALPHA BLOCKERS		
alfuzosin ER	CARDURA (doxazosin)	
doxazosin	CARDURA XL (doxazosin)	
tamsulosin	dutasteride/tamsulosin	
terazosin	FLOMAX (tamsulosin)	
	RAPAFLO (silodosin)	
	silodosin	
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS		
	CIALIS (tadalafil)	
	tadalafil	
BRONCHODILATORS & COPD AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTICHOLINERGIC-BETA AGONIST COMBINATIONS		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> 4 years: SEREVENT, XOPENEX HFA 6 years: SPIRIVA RESPIMAT, XOPENEX Solution 18 years: BROVANA, BREZTRI AEROSPHERE, PERFORMOMIST, STRIVERDI RESPIMAT, TRELEGY ELLIPTA <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> 1 claim for a preferred agent in the past 6 months OR 3 claims with the requested agent in the past 105 days
ANORO ELLIPTA (umeclidinium/vilanterol)	BEVESPI AEROSPHERE (glycopyrrolate/formoterol)	
COMBIVENT RESPIMAT (ipratropium/albuterol)	DUAKLIR PRESSAIR (aclidinium/formoterol)	
ipratropium/albuterol		
STIOLTO RESPIMAT (tiotropium/olodaterol)		
ANTICHOLINERGIC-BETA AGONIST-GLUCOCORTICOID COMBINATIONS ^{DUR+}		
BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol)		
TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol)		
ANTICHOLINERGICS AND COPD AGENTS		<p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> 10.7 units BREZTRI AEROSPHERE <p>BREZTRI AEROSPHERE</p> <ul style="list-style-type: none"> Documented diagnosis of COPD AND 1 claim with the BREZTRI AEROSPHERE or TRELEGY ELLIPTA in the past 105 days <p>OR</p> <ul style="list-style-type: none"> Documented diagnosis of COPD AND 60 days of therapy with a preferred anticholinergic product in the past 90 days AND 60 days of therapy with a preferred ICS-LABA product in the past 90 days <p>TRELEGY ELLIPTA</p> <ul style="list-style-type: none"> Documented diagnosis of asthma or COPD AND 1 claim with the BREZTRI AEROSPHERE or TRELEGY ELLIPTA in the past 105 days <p>OR</p> <ul style="list-style-type: none"> Documented diagnosis of asthma or COPD AND 60 days of therapy with a preferred anticholinergic product in the past 90 days AND 60 days of therapy with a preferred ICS-LABA product in the past 90 days
ATROVENT HFA (ipratropium)	DALIRESP (roflumilast)	
ipratropium solution	INCRUSE ELLIPTA (umeclidinium)	
SPIRIVA HANDHALER (tiotropium)	ipratropium HFA ^{NR}	
SPIRIVA RESPIMAT (tiotropium)	OHTUVAYRE (ensifentrine)	
	roflumilast	

	tiotropium	XOPENEX HFA and Solution <ul style="list-style-type: none"> 1 claim for a preferred albuterol (inhaler or vials) in the past 30 days
	TUDORZA PRESSAIR (aclidinium)	
	umeclidinium ellipta	
	YUPELRI (revefenacin)	
INHALATION SOLUTION DUR+		
albuterol	arformoterol	
	BROVANA (arformoterol)	
	formoterol, formoterol fumarate	
	levalbuterol	
	PERFOROMIST (formoterol)	
INHALERS, LONG ACTING DUR+		
SEREVENT DISKUS (salmeterol)		
STRIVERDI RESPIMAT (olodaterol)		
INHALERS, SHORT ACTING		
albuterol HFA	levalbuterol HFA	
VENTOLIN HFA (albuterol)	PROAIR DIGIHALER (albuterol)	
	XOPENEX HFA (levalbuterol)	
ORAL		
albuterol IR	albuterol ER	
terbutaline		
CALCIUM CHANNEL BLOCKERS DUR+		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LONG-ACTING		Quantity Limit (per 21 days) <ul style="list-style-type: none"> 252 capsules: nimodipine 2520 mL: nimodipine Non-Preferred Criteria Long Acting <ul style="list-style-type: none"> Have tried 2 different preferred Long Acting CCB agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days Non-Preferred Criteria Short Acting <ul style="list-style-type: none"> Have tried 2 different preferred Short Acting CCB agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days CARDAMYST, SDAMLO <ul style="list-style-type: none"> Requires clinical review nimodipine <ul style="list-style-type: none"> Documented diagnosis of subarachnoid hemorrhage in the past 45 days AND Duration of therapy limited to 21 days
amlodipine	diltiazem ER 12 HR	
CARTIA XT (diltiazem)	diltiazem LA 24 HR	
diltiazem ER 24 HR	KATERZIA (amlodipine)	
diltiazem CD 24 HR	levamlodipine	
diltiazem XR 24 HR	MATZIM LA (diltiazem)	
DILT-XR 24 HR (diltiazem)	nisoldipine	
felodipine	NORLIQVA (amlodipine)	
nifedipine ER	NORVASC (amlodipine)	
TAZTIA XT (diltiazem)	PROCARDIA XL (nifedipine)	
TIADYLT ER (diltiazem)	SDAMLO (amlodipine) ^{NR}	
verapamil ER	SULAR (nisoldipine)	
verapamil SR	TIAZAC (diltiazem)	
	verapamil PM	
	VERELAN PM (verapamil)	
SHORT-ACTING		
diltiazem	CARDAMYST (etripamil) ^{NR}	
nicardipine	isradipine	
nifedipine	nimodipine	
verapamil	NYMALIZE (nimodipine)	
CALORIC AGENTS		

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BOOST	All non-preferred caloric/nutritional agents (which are all other products except those specifically listed as preferred) require a manual prior authorization.	Non-Preferred Agents MANUAL PA
BREAKFAST ESSENTIALS		
BRIGHT BEGINNINGS		
DUOCAL		
ENSURE		
NUTREN		
OSMOLITE		
PEDIASURE		
PROMOD		
RESOURCE		
TWOCAL HN		

CEPHALOSPORINS AND RELATED ANTIBIOTICS (ORAL)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS		Non-Preferred Criteria All Cephalosporin Generations <ul style="list-style-type: none"> Have tried 2 different preferred agents in the past 6 months Maximum Age Limit <ul style="list-style-type: none"> 18 years: cefdinir suspension
amoxicillin/clavulanate	amoxicillin/clavulanate ER	
	AUGMENTIN (amoxicillin/clavulanate)	
CEPHALOSPORINS FIRST GENERATION		
cefadroxil capsule, suspension	cefadroxil tablet	
cephalexin capsule, suspension	cephalexin tablet	
CEPHALOSPORINS SECOND GENERATION		
cefaclor capsule	cefaclor ER	
cefprozil	cefaclor suspension	
cefuroxime		
CEPHALOSPORINS THIRD GENERATION		
cefdinir	cefixime suspension, tablet ^{NR}	
cefixime capsule	SUPRAX (cefixime)	
cefpodoxime		

COLONY STIMULATING FACTORS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LONG-ACTING		
FULPHILA (pegfilgrastim-jmdb)	FYLNETRA (pegfilgrastim-pbbk)	
	NEULASTA, NEULASTA ONPRO (pegfilgrastim)	
	NYVEPRIA (pegfilgrastim-apgf)	
	RYZNEUTA (efbemalenograstim alfa-vuxw)	
	ROLVEDON (eflapegrastim-xnst)	

	STIMUFEND (pegfilgrastim-fpgk)
	UDENYCA, UDENYCA ONBODY (pegfilgrastim-cbqv)
	ZIEXTENZO (pegfilgrastim-bmez)
SHORT-ACTING	
NEUPOGEN (filgrastim)	FILKRI (filgrastim-laha) ^{NR}
RELEUKO (filgrastim-ayow)	GRANIX (tbo-filgrastim)
	LEUKINE (sargramostim)
	NIVESTYM (filgrastim-aafi)
	NYPOZL (filgrastim-txid)
	ZARXIO (filgrastim-sndz)

CYSTIC FIBROSIS AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PULMOZYME (dornase alfa)	ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 1 month: KALYDECO granules • 3 months: PULMOZYME • 1 year: ORKAMBI • 2 years: COLY-MYCIN M, TRIKAFTA granules • 6 years: ALYFTREK, BETHKIS, KALYDECO tablet, KITABIS, SYMDEKO, TOBI, TOBI PODHALER, TRIKAFTA tablet • 7 years: CAYSTON • 18 years: BRONCHITOL <p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 2 years: ORKAMBI 75-94 mg granules • 5 years: KALYDECO, ORKAMBI 100-125 mg granules, ORKAMBI 200-125 mg granules, TRIKAFTA granules • 11 years: TRIKAFTA 50-25-37.5 mg tablets <p>Preferred Agents</p> <ul style="list-style-type: none"> • Documented diagnosis of Cystic Fibrosis OR • Require clinical review <p>ALYFTREK MANUAL PA</p> <p>KALYDECO MANUAL PA</p> <p>ORKAMBI MANUAL PA</p> <p>SYMDEKO MANUAL PA</p> <p>TOBI PODHALER Require clinical review</p> <p>TRIKAFTA MANUAL PA</p>
tobramycin (generic TOBI)	BETHKIS (tobramycin)	
	BRONCHITOL (mannitol)	
	CAYSTON (aztreonam)	
	colistimethate	
	COLY-MYCIN M (colistin)	
	KALYDECO (ivacaftor)	
	KITABIS (tobramycin)	
	ORKAMBI (lumacaftor/ivacaftor)	
	SYMDEKO (tezacaftor/ivacaftor)	
	TOBI (tobramycin)	
	TOBI PODHALER (tobramycin)	
	tobramycin (generic BETHKIS & KITABIS)	
	TRIKAFTA (elexacaftor/tezacaftor/ivacaftor)	

CYTOKINE & CAM ANTAGONISTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
adalimumab-aaty autoinject	ABRILADA (adalimumab-afzb)	Non-Preferred Agents

AVSOLA (infliximab-axxq)	ACTEMRA (tocilizumab)	• Require clinical review
CYLTEZO (adalimumab-adbm)	adalimumab-aaty syringe	IV Administered Agents
ENBREL (etanercept)	adalimumab-adaz	• Require clinical review
HADLIMA (adalimumab-bwwd)	adalimumab-adbm	adalimumab-aaty autoinject, HADLIMA (adalimumab-bwwd), and YUFLYMA (adalimumab-aaty) – Age specific indications:
HUMIRA (adalimumab)	adalimumab-fkjp	• Age 2 years and older AND
IMULDOSA (ustekinumab-srif)	adalimumab-ryvk	• Diagnosis of juvenile idiopathic arthritis (JIA)
KINERET (anakinra)	AMJEVITA (adalimumab-atto)	• Age 6 years and older AND
methotrexate	ARCALYST (rilonacept)	• Diagnosis of Crohn's disease (CD)
OLUMIANT (baricitinib)	AVTOZMA (tocilizumab-anoh)	• Age 18 years and older AND
ORENCIA CLICKJECT (abatacept)	AVTOZMA AUTOINJECTOR (tocilizumab-anoh)	• Diagnosis of rheumatoid arthritis (RA) OR
ORENCIA VIAL (abatacept)	BIMZELX (bimekizumab-bkzx)	• Diagnosis of plaque psoriasis (PsO) OR
OTEZLA (apremilast)	CIMZIA (certolizumab)	• Diagnosis of psoriatic arthritis (PsA) OR
PYZCHIVA (ustekinumab-ttwe)	COSENTYX (secukinumab)	• Diagnosis of ulcerative colitis (UC) OR
RINVOQ (upadacitinib)	ENTYVIO (vedolizumab)	• Diagnosis of hidradenitis suppurativa (HS) OR
RINVOQ LQ (upadacitinib)	HULIO (adalimumab-fkjp)	• Diagnosis of ankylosing spondylitis (AS) OR
SELARSDI (ustekinumab-aekn)	HYRIMOZ (adalimumab-adaz)	• Diagnosis of uveitis (UV)
SIMPONI (golimumab)	ICOTYDE (icotrokinra) ^{NR}	AVSOLA (infliximab-axxq) – Age specific indications:
STARJEMZA (ustekinumab-hmny)	IDACIO (adalimumab-aacf)	• Age 6 years and older AND
TALTZ (ixekizumab)	ILARIS (canakinumab)	• Diagnosis of Crohn's disease OR
TYENNE (tocilizumab-aazg)	ILUMYA (tildrakizumab-asmn)	• Diagnosis of ulcerative colitis
ustekinumab-aaaz	INFLECTRA (infliximab-dyyb)	• Age 18 years and older AND
XELJANZ (tofacitinib) tablet	infliximab	• Diagnosis of rheumatoid arthritis (RA) OR
YUFLYMA (adalimumab-aaty)	JYLAMVO (methotrexate)	• Diagnosis of plaque psoriasis (PsO) OR
	KEVZARA (sarilumab)	• Diagnosis of psoriatic arthritis (PsA) OR
	LEQSELVI (deuruxolitinib)	• Diagnosis of ankylosing spondylitis (AS)
	LITFULO (ritlectinib)	CYLTEZO (adalimumab-adbm) – Age specific indications:
	OMVOH (mirikizumab-mrkz)	• Age 2 years and older AND
	ORENCIA SYRINGE (abatacept)	• Diagnosis of juvenile idiopathic arthritis (JIA) OR
	OTEZLA XR (apremilast)	• Diagnosis of uveitis (UV)
	OTREXUP (methotrexate)	• Age 6 years and older AND
	OTULFI (ustekinumab-aaaz)	• Diagnosis of Crohn's disease (CD)
	RASUVO (methotrexate)	• Age 12 years and older AND
	REMICADE (infliximab)	• Diagnosis of hidradenitis suppurativa (HS)
	RENFLEXIS (infliximab-abda)	• Age 18 years and older AND
	SIMLANDI (adalimumab-ryvk)	• Diagnosis of rheumatoid arthritis (RA) OR
	SIMPONI ARIA (golimumab)	• Diagnosis of plaque psoriasis (PsO) OR
	SKYRIZI (risankizumab-rzaa)	• Diagnosis of psoriatic arthritis (PsA) OR
		• Diagnosis of ulcerative colitis (UC) OR
		• Diagnosis of ankylosing spondylitis (AS)
		ENBREL (etanercept) – Age specific indications:
		• Age 2 years and older AND
		• Diagnosis of juvenile arthritis (JIA) OR
		• Diagnosis of juvenile psoriatic arthritis (PsA)

	SOTYKTU (deucravacitinib)	
	SPEVIGO (spesolimab-sbzo)	<ul style="list-style-type: none"> • Age 4 years and older AND • Diagnosis of plaque psoriasis (PsO)
	STELARA (ustekinumab)	
	STEQEYMA (ustekinumab-stba)	<ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of rheumatoid arthritis (RA) OR • Diagnosis of psoriatic arthritis (PsA) OR • Diagnosis of ankylosing spondylitis (AS)
	TOFIDENCE (tocilizumab-bavi)	
	TREMFYA (guselkumab)	
	TREXALL (methotrexate)	HUMIRA (adalimumab) – Age specific indications:
	ustekinumab	<ul style="list-style-type: none"> • Age 2 years and older AND • Diagnosis of juvenile idiopathic arthritis (JIA) OR • Diagnosis of uveitis (UV)
	ustekinumab-aekn	
	ustekinumab-ttwe	
	XATMEP (methotrexate)	
	XELJANZ (tofacitinib) solution	<ul style="list-style-type: none"> • Age 5 years and older AND • Diagnosis of ulcerative colitis (UC)
	XELJANZ XR (tofacitinib)	<ul style="list-style-type: none"> • Age 6 years and older AND • Diagnosis of Crohn's disease (CD)
	YESINTEK (ustekinumab-kfce)	
	YUSIMRY (adalimumab-aqvh)	<ul style="list-style-type: none"> • Age 12 years and older AND • Diagnosis of hidradenitis suppurativa (HS)
	ZYMFENTRA (infliximab-dyyb)	<ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of rheumatoid arthritis (RA) OR • Diagnosis of plaque psoriasis (PsO) OR • Diagnosis of psoriatic arthritis (PsA) OR • Diagnosis of ankylosing spondylitis (AS) <p>IMULDOSA (ustekinumab-srlf), PYZCHIVA (ustekinumab-ttwe), SELARSDI (ustekinumab-aekn), STARJEMZA (ustekinumab-hmny), and ustekinumab-aaaz – Age specific indications:</p> <ul style="list-style-type: none"> • Age 6 years and older AND • Diagnosis of plaque psoriasis (PsO) OR • Diagnosis of psoriatic arthritis (PsA) <ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of ulcerative colitis (UC) OR • Diagnosis of Crohn's disease (CD) <p>KINERET (anakinra) – Age specific indications:</p> <ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of rheumatoid arthritis (RA) • Other indications require clinical review <p>OLUMIANT (baricitinib) – Age specific indications:</p> <ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of alopecia areata (AA) • Other indications require clinical review <p>ORENCIA (abatacept) – Age specific indications:</p> <ul style="list-style-type: none"> • Age 2 years and older AND • Diagnosis of juvenile arthritis (JIA) OR • Diagnosis of psoriatic arthritis (PsA) • Other indication requires clinical review <ul style="list-style-type: none"> • Age 18 years and older AND

- Diagnosis of rheumatoid arthritis (RA)
 - Non-preferred Orenzia syringe requires clinical review
- OTEZLA (apremilast) – Age specific indications:**
- Age 6 years and older **AND**
 - Diagnosis of plaque psoriasis (PsO) **OR**
 - Diagnosis of psoriatic arthritis (PsA)
- Age 18 years and older **AND**
 - Diagnosis of Bechet's disease
 - Non-preferred Otezla XR requires clinical review
- RINVOQ (upadacitinib):**
- Age 2 years and older **AND**
 - Diagnosis of juvenile idiopathic arthritis (JIA) **OR**
 - Diagnosis of psoriatic arthritis
- AND**
- History of 3 claims with preferred TNF Inhibitor Avsola, Enbrel, Humira or Simponi
- OR**
- History of 1 claim with Rinvoq in the past
- AND**
- NO history of concomitant therapy in the past 30 days with any of the following:
 - A different JAK Inhibitor
 - A different biologic
 - Immunosuppressant azathioprine or cyclosporine
- Age 18 years and older **AND**
 - Diagnosis of ankylosing spondylitis **OR**
 - Diagnosis of Crohn's disease **OR**
 - Diagnosis of giant cell arteritis **OR**
 - Diagnosis of active non-radiographic axial spondyloarthritis (nr-axSpA) **OR**
 - Diagnosis of rheumatoid arthritis (RA) **OR**
 - Diagnosis of ulcerative colitis
- AND**
- History of 3 claims with preferred TNF Inhibitor Avsola, Enbrel, Humira or Simponi
- OR**
- History of 1 claim with Rinvoq in the past
- AND**
- NO history of concomitant therapy in the past 30 days with any of the following:
 - A different JAK Inhibitor
 - A different biologic
 - Immunosuppressant azathioprine or cyclosporine
- Atopic Dermatitis **MANUAL PA**
- SIMPONI (golimumab) – Age specific indications:**
- Age 18 years and older **AND**
 - Diagnosis of rheumatoid arthritis (RA) **OR**
 - Diagnosis of psoriatic arthritis (PsA) **OR**
 - Diagnosis of ankylosing spondylitis (AS) **OR**
 - Diagnosis of ulcerative colitis
 - Ages less than 18 years require clinical review
 - Non-preferred Simponi Aria requires clinical review
- STELARA MANUAL PA**

		<p>TALTZ (ixekizumab) – Age specific indications: Taltz 20 mg, 40 mg and 80 mg</p> <ul style="list-style-type: none"> • Age 6 AND • Diagnosis of plaque psoriasis (PsO) <p>Taltz 80 mg</p> <ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of psoriatic arthritis (PsA) OR • Diagnosis of ankylosing spondylitis (AS) OR • Diagnosis of active non-radiographic axial spondyloarthritis (nr-axSpA) <p>TYENNE (tocilizumab-aazg) – Age specific indications:</p> <ul style="list-style-type: none"> • Age 2 years and older AND • Diagnosis of juvenile arthritis (JIA) <ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of rheumatoid arthritis (RA) OR • Diagnosis of giant cell arteritis <p>XELJANZ IR (tofacitinib) – Any of the following:</p> <ul style="list-style-type: none"> • Age 2 year and older AND • Diagnosis of juvenile arthritis (JIA) OR • Diagnosis of psoriatic arthritis (PsA) <ul style="list-style-type: none"> • Age 18 years and older AND • Diagnosis of rheumatoid arthritis (RA) OR • Diagnosis of ulcerative colitis (UC) OR • Diagnosis of ankylosing spondylitis (AS) • Non-preferred Xeljanz oral solution and Xeljanz XR require clinical review <p>Preferred methotrexate does not require prior authorization</p>
--	--	--

ERYTHROPOIESIS STIMULATING PROTEINS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
EPOGEN (epoetin alfa)	ARANESP (darbepoetin alfa)	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Documented diagnosis of cancer or chronic renal failure OR • Antineoplastic therapy in the past 6 months AND • Have tried a preferred RETACRIT or EPOGEN in the past 6 months OR • 1 claim for the requested agent in the past 105 days <p>JESDUVROQ</p> <ul style="list-style-type: none"> • Requires clinical review <p>MIRCERA</p> <ul style="list-style-type: none"> • Documented diagnosis of chronic renal failure in the past 2 years
MIRCERA (methoxy polyethylene glycol-epoetin-beta)	JESDUVROQ (daprodustat)	
RETACRIT (epoetin alfa-epbx)	PROCRIT (epoetin alfa)	
	VAFSEO (vadadustat)	

FACTOR DEFICIENCY PRODUCTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
FACTOR VIII		<p>HEMLIBRA</p> <ul style="list-style-type: none"> • 3 claims with HEMLIBRA in the past 105 days OR • New starts require clinical review MANUAL PA
ADVATE	ADYNOVATE	
AFSTYLA	ELOCTATE	

ALPHANATE	ESPEROCT
ALTUVIIIIO	JIVI
FEIBA	KCENTRA
HEMOFIL M	OBIZUR
HUMATE-P	VONVENDI
KOATE	
KOGENATE FS	
KOVALTRY	
NOVOEIGHT	
NUWIQ	
RECOMBINATE	
WILATE	
XYNTHA, XYNTHA SOLOFUSE	
FACTOR IX	
ALPHANINE SD	BEQVEZ
ALPROLIX	
BENEFIX	
IDELVION	
IXINITY	
PROFILNINE	
REBINYN	
RIXUBIS	
OTHER HEMOPHILIA PRODUCTS	
COAGADEX (factor X)	ALHEMO (concizumab-mtci)
FIBRYGA (fibrinogen)	CORIFACT (factor XIII)
HEMLIBRA (emicizumab-kxwh) ^{DUR+}	FESILTY (fibrinogen) ^{NR}
RIASTAP (fibrinogen)	HYMPAVZI (marstacimab-hncq)
	NOVOSEVEN RT (factor VII)
	QFITLIA (fitusiran)
	SEVENFACT (factor VII)
	TRETTEN (factor XIII)

FIBROMYALGIA/NEUROPATHIC PAIN AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
duloxetine 20 mg, 30 mg, 60 mg DR capsule	CYMBALTA (duloxetine)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: CYMBALTA, DRIZALMA SPRINKLE, duloxetine DR capsule <p>TONMYA MANUAL PA</p> <p>RELGAABI</p> <ul style="list-style-type: none"> • Requires clinical review
gabapentin	DRIZALMA SPRINKLE (duloxetine)	
pregabalin	duloxetine 40 mg DR capsule	
SAVELLA (milnacipran)	gabapentin ER	
	GABARONE (gabapentin)	
	GRALISE (gabapentin)	
	HORIZANT (gabapentin enacarbil)	
	LYRICA, LYRICA CR (pregabalin)	
	milnacipran ^{NR}	
	NEURONTIN (gabapentin)	

	pregabalin ER	
	RELGAABI (gabapentin)	
	TONMYA (cyclobenzaprine)	

FLUOROQUINOLONES ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ciprofloxacin tablet	BAXDELA (delafloxacin)	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • 1 claim for a preferred agent in the past 30 days <p>CIPRO Suspension for Age < 12 Years</p> <ul style="list-style-type: none"> • Documented diagnosis of Cystic Fibrosis or Anthrax infection or exposure OR • Documented diagnosis or Pneumonic plague or tularemia AND • History of doxycycline in the past 3 months OR • 7 days of therapy with a preferred agent from 2 of the classes below in the past 3 months: <ul style="list-style-type: none"> ◦ Penicillin, 2nd or 3rd generation cephalosporin or macrolide <p>LEVAQUIN Suspension for Age < 12 Years</p> <ul style="list-style-type: none"> • Documented diagnosis of Anthrax infection or exposure OR • History of 7 days of therapy with a preferred from 2 of the following classes in the past 3 months <ul style="list-style-type: none"> ◦ Penicillin, 2nd or 3rd generation cephalosporins, or macrolide AND • History of ciprofloxacin suspension in the past 3 months
levofloxacin tablet	CIPRO (ciprofloxacin)	
	ciprofloxacin suspension	
	levofloxacin solution	
	moxifloxacin	
	ofloxacin	

GAUCHER'S DISEASE

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ELELYSO (taliglucerase alfa)	CERDELGA (eliglustat)	
ZAVESCA (miglustat)	CEREZYME (imiglucerase)	
	miglustat	
	VPRIV (velaglucerase alfa)	
	YARGESA (miglustat)	

GENITAL WARTS & ACTINIC KERATOSIS AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CONDYLOX (podofilox)	VEREGEN (sinecatechins)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 12 years: ALDARA • 18 years: CONDYLOX, PICATO, VEREGEN
fluorouracil		
imiquimod		
podofilox		

GI ULCER THERAPIES

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
H2 RECEPTOR ANTAGONISTS		<p>PRILOSEC 2.5 mg suspension</p> <ul style="list-style-type: none"> • Automatic approval issued for 0-2 years of age <p>PRILOSEC 10 mg suspension</p> <ul style="list-style-type: none"> • Requires clinical review
famotidine	cimetidine	
	nizatidine	
	ranitidine	
OTHERS		
CARAFATE (sucralfate) suspension	CARAFATE (sucralfate) tablet	
misoprostol	CYTOTEC (misoprostol)	
sucralfate	DARTISLA (glycopyrrolate)	

	EOHILIA (budesonide)
	VOQUEZNA (vonoprazan)
PROTON PUMP INHIBITORS	
esomeprazole capsule	DEXILANT (dexlansoprazole)
NEXIUM (esomeprazole) packet	dexlansoprazole
omeprazole	esomeprazole packet
pantoprazole	KONVOMEK (omeprazole/sodium bicarbonate)
	lansoprazole Rx
	NEXIUM (esomeprazole) capsule
	omeprazole/sodium bicarbonate
	PREVACID (lansoprazole)
	PRILOSEC (omeprazole) packet
	PROTONIX (pantoprazole)
	rabeprazole
	ZEGERID (omeprazole/sodium bicarbonate)

GLUCOCORTICOIDS (INHALED)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GLUCOCORTICOIDS		
ASMANEX (mometasone)	ALVESCO (ciclesonide)	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Glucocorticoids <ul style="list-style-type: none"> ○ 2 preferred single-entity agents in the past 6 months OR ○ 90 days of therapy with the requested agent in the past 105 days • Glucocorticoid/Bronchodilator Combinations <ul style="list-style-type: none"> ○ 2 preferred combination agents in the past 6 months OR ○ 90 days of therapy with the requested agent in the past 105 days • Note: <ul style="list-style-type: none"> ○ Institutional-sized products are non-preferred <p>AIRDUO DIGIHALER</p> <ul style="list-style-type: none"> • Requires clinical review <p>ARMONAIR DIGIHALER</p> <ul style="list-style-type: none"> • Requires clinical review <p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: AIRSUPRA <p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 2 inhalers: AIRSUPRA MANUAL PA
budesonide 0.25 mg and 0.5 mg	ARMONAIR DIGIHALER (fluticasone)	
fluticasone	ARNUITY ELLIPTA (fluticasone)	
fluticasone diskus	ASMANEX HFA (mometasone)	
fluticasone HFA	beclomethasone ^{NR}	
QVAR REDIHALER (beclomethasone)	budesonide 1 mg	
	FLOVENT HFA (fluticasone)	
	FLOVENT DISKUS (fluticasone)	
	PULMICORT (budesonide) nebulizer solution	
GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS		
ADVAIR DISKUS (fluticasone/salmeterol)	AIRDUO DIGIHALER (fluticasone/salmeterol)	
ADVAIR HFA (fluticasone/salmeterol)	AIRSUPRA (albuterol/budesonide)	
DULERA (mometasone/formoterol)	BREO ELLIPTA (fluticasone/vilanterol)	
fluticasone/salmeterol diskus	BREYNA (budesonide/formoterol)	

SYMBICORT (budesonide/formoterol)	budesonide/formoterol	
	fluticasone/salmeterol HFA	
	fluticasone/vilanterol	
	WIXELA INHUB (fluticasone/salmeterol)	

GROWTH HORMONES ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GENOTROPIN (somatropin)	HUMATROPE (somatropin)	<p>Preferred Criteria</p> <ul style="list-style-type: none"> • Age ≥ 18 years • Documented diagnosis of craniopharyngioma, HIV associated cachexia, iatrogenic growth deficiency due to drug-induced or post-procedural hypopituitarism, Noonan Syndrome, panhypopituitarism, Prader-Willi Syndrome, renal function impairment growth disorders, short stature shox deficiency, Turner Syndrome or history of cranial irradiation • Age < 18 years • Diagnosis of approvable pediatric diagnosis or history of cranial irradiation <p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 3 years: NGENLA <p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 18 years: NGENLA <p>Non-Preferred Criteria</p> <p>Age ≥ 18 years</p> <ul style="list-style-type: none"> • Documented approvable diagnosis for age as above diagnosis of craniopharyngioma, HIV associated cachexia, iatrogenic growth deficiency due to drug-induced or post-procedural hypopituitarism, Noonan Syndrome, panhypopituitarism, Prader-Willi Syndrome, renal function impairment growth disorders, short stature shox deficiency, Turner Syndrome or history of cranial irradiation AND • History of 28 days of therapy with a preferred Growth Hormone in the past 6 months OR • 84 days of therapy with the requested agent in the past 105 days <p>Age < 18 years</p> <ul style="list-style-type: none"> • Diagnosis of congenital malformation syndrome, HIV associated cachexia, hypopituitarism, iatrogenic growth deficiency due to drug-induced or post-procedural hypopituitarism, mosaicism 45, Prader-Willi Syndrome, renal function impairment growth disorders, short stature due to endocrine disorder, small for gestational age or Turner Syndrome AND • History of 28 days of therapy with a preferred Growth Hormone in the past 6 months OR • 84 days of therapy with the requested agent in the past 105 days <p>SKYTROFA</p> <p>Age ≥ 18 years</p> <ul style="list-style-type: none"> • Documented diagnosis of craniopharyngioma, HIV associated cachexia, iatrogenic growth deficiency growth deficiency due to drug-induced or post-procedural hypopituitarism, Noonan Syndrome, panhypopituitarism, renal function impairment growth disorders, short stature shox deficiency, Turner Syndrome or history of cranial irradiation AND • No history of diagnosis of Prader Willi Syndrome AND • History of 28 days of therapy with a preferred Short-Acting Growth Hormone in the past 6 months OR • 84 days of therapy with Skytrofa in the past 105 days <p>Age < 18 years</p> <ul style="list-style-type: none"> • No history of diagnosis of Prader Willi Syndrome AND • History of 28 days of therapy with a preferred Short-Acting Growth Hormone in the past 6 months OR • 84 days of therapy with Skytrofa in the past 105 days
NORDITROPIN FLEXPRO (somatropin)	NGENLA (somatrogon-ghla)	
SKYTROFA (lonapegsomatropin-tcgd)	OMNITROPE (somatropin)	
	SEROSTIM (somatropin)	
	SOGROYA (somapacitan-beco)	
	ZOMACTON (somatropin)	

H. PYLORI COMBINATION TREATMENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PYLERA (bismuth subcitrate potassium/metronidazole/tetracycline)	bismuth subcitrate potassium/metronidazole/tetracycline	Quantity Limit <ul style="list-style-type: none"> • 1 treatment course/year: all agents
	lansoprazole/amoxicillin/clarithromycin	
	OMECLAMOX (omeprazole/clarithromycin/amoxicillin)	
	TALICIA (omeprazole/amoxicillin/rifabutin)	
	VOQUEZNA DUAL PAK (vonoprazan/amoxicillin)	
	VOQUEZNA TRIPLE PAK (vonoprazan/amoxicillin/clarithromycin)	
HEPATITIS B TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
entecavir	adefovir dipivoxil	
lamivudine HBV	BARACLUDE (entecavir)	
tenofovir disoproxil fumarate	VEMLIDY (tenofovir alafenamide)	
	VIREAD (tenofovir disoproxil fumarate)	
HEPATITIS C TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MAVYRET (glecaprevir/pibrentasvir)	EPCLUSA (sofosbuvir/velpatasvir)	EPCLUSA, HARVONI, MAVYRET, SOVALDI, VOSEVI, ZEPATIER <ul style="list-style-type: none"> • Require MANUAL PA Note: <ul style="list-style-type: none"> • EPCLUSA, HARVONI, MAVYRET and SOVALDI have FDA-approved pediatric indications
PEGASYS (peginterferon alfa-2a)	HARVONI (ledipasvir/sofosbuvir)	
ribavirin tablet	ledipasvir/sofosbuvir	
sofosbuvir/velpatasvir	ribavirin capsule	
	SOVALDI (sofosbuvir)	
	VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir)	
	VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)	
	ZEPATIER (elbasvir/grazoprevir)	
HEREDITARY ANGIOEDEMA TREATMENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
PROPHYLAXIS		Non-Preferred Criteria <ul style="list-style-type: none"> • Requires clinical review
HAEGARDA (C1 esterase inhibitor)	ANDEMBRY (garadacimab-gxii)	

	CINRYZE (C1 esterase inhibitor)	
	DAWNZERA (donidalorsen)	
	ORLADEYO (berotralstat)	
	TAKHZYRO (lanadelumab-flyo)	
ACUTE TREATMENT		
BERINERT (C1 esterase inhibitor)	EKTERLY (sebtralstat)	
icatibant	FIRAZYR (icatibant)	
	KALBITOR (ecallantide)	
	RUCONEST (C1 esterase inhibitor)	
	SAJAZIR (icatibant)	
HYPERURICEMIA & GOUT ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
allopurinol	ALOPRIM (allopurinol)	Non-Preferred Criteria <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
colchicine tablet	colchicine capsule	
probenecid	COLCRYS (colchicine)	
probenecid/colchicine	febuxostat	
	GLOPERBA (colchicine)	
	MITIGARE (colchicine)	
	ULORIC (febuxostat)	
	ZYLOPRIM (allopurinol)	
HYPOGLYCEMIA TREATMENT		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BAQSIMI (glucagon)	GVOKE (glucagon) ^{Step Edit}	Minimum Age Limit <ul style="list-style-type: none"> • 1 year: BAQSIMI • 2 years: GVOKE • 6 years: ZEGALOGUE Quantity Limit (per 31 days) <ul style="list-style-type: none"> • 2 packs (or kits): BAQSIMI, glucagon, GVOKE, ZEGALOGUE Non-Preferred Criteria GVOKE <ul style="list-style-type: none"> • 1 claim with preferred BAQSIMI or ZEGALOGUE in the past 30 days
GLUCAGEN (glucagon)		
glucagon emergency kit		
glucagon vial		
ZEGALOGUE (dasiglucagon)		
HYPOGLYCEMICS, BIGUANIDES		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
metformin 500 mg, 850 mg, 1,000 mg tablets	GLUMETZA (metformin)	
metformin ER (generic GLUCOPHAGE XR)	metformin 625 mg, 750 mg tablets	
	metformin ER (generic FORTAMET)	
	metformin ER (generic GLUMETZA)	
	metformin solution	

	RIOMET (metformin)	
HYPOGLYCEMICS, DPP4s AND COMBINATIONS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
JANUMET (sitagliptin/metformin)	alogliptin	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred DPP4 agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days <p>Note: Concomitant use of a GLP-1 agent and a DPP-4 agent requires clinical review</p> <p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: BRYNOVIN solution
JANUMET XR (sitagliptin/metformin)	alogliptin/metformin	
JANUVIA (sitagliptin)	BRYNOVIN solution (sitagliptin)	
JENTADUETO (linagliptin/metformin)	JENTADUETO XR (linagliptin/metformin)	
TRADJENTA (linagliptin)	KAZANO (alogliptin/metformin)	
	KOMBIGLYZE XR (saxagliptin/metformin)	
	linagliptin/metformin	
	NESINA (alogliptin)	
	ONGLYZA (saxagliptin)	
	OSENI (alogliptin/pioglitazone)	
	saxagliptin	
	saxagliptin/metformin ER	
	sitagliptin	
	sitagliptin/metformin	
	ZITUVIMET (sitagliptin/metformin)	
	ZITUVIMET XR (sitagliptin/metformin)	
	ZITUVIO (sitagliptin)	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BYETTA (exenatide)	BYDUREON (exenatide)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 10 years: BYDUREON BCISE, MOUNJARO, TRULICITY, VICTOZA • 18 years: BYETTA, OZEMPIC, RYBELSUS <p>Preferred Criteria</p> <ul style="list-style-type: none"> • Documented diagnosis of Type 2 Diabetes AND • No history of SAXENDA or WEGOVY in the past 30 days <p>OR</p> <ul style="list-style-type: none"> • No documented diagnosis for Type 2 Diabetes AND • 84 days of therapy with the requested agent in the past 105 days <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Documented diagnosis of Type 2 Diabetes AND • No history of SAXENDA or WEGOVY in the past 30 days AND • 84 days of therapy with TRULICITY in the past 6 months AND • 84 days of therapy with either preferred BYETTA or VICTOZA in the past 6 months <p>OR</p> <ul style="list-style-type: none"> • Documented diagnosis of Type 2 Diabetes AND • 84 days of therapy with the request agent in the past 105 days <p>Note:</p>
TRULICITY (dulaglutide)	exenatide	
VICTOZA (liraglutide)	liraglutide	
	MOUNJARO (tirzepatide)	
	OZEMPIC (semaglutide)	
	RYBELSUS (semaglutide)	
	SOLIQUA (insulin glargine/lixisenatide)	
	SYMLINPEN (pramlintide)	
	XULTOPHY (insulin degludec/liraglutide)	

		<ul style="list-style-type: none"> Concomitant use of a GLP-1 agonist and a DPP-4 agent requires clinical review. Please see the PDL category Anti-obesity Select Agents for a list of covered agents. <p>RYBELSUS 1.5 mg and 3 mg</p> <ul style="list-style-type: none"> Requires clinical review
--	--	--

HYPOGLYCEMICS, INSULINS & RELATED AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HUMALOG MIX 75/25 vial (insulin lispro/lispro protamine)	ADMELOG (insulin lispro)	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> Documented diagnosis of Diabetes Mellitus AND Have tried 1 preferred agent in the past 6 months OR 1 claim with the requested agent in the past 105 days
HUMULIN 70/30 vial (insulin NPH/regular)	AFREZZA (insulin regular)	
HUMULIN N (insulin NPH)	APIDRA (insulin glulisine)	<p>Quantity Limit</p> <ul style="list-style-type: none"> Insulin quantity limits can be found here
HUMULIN R (insulin regular)	BASAGLAR (insulin glargine)	
HUMULIN R U-500 (insulin regular)	FIASP (insulin aspart/niacinamide)	<p>Note:</p> <ul style="list-style-type: none"> Insulin pen formulations are not covered for Long Term Care (LTC) beneficiaries.
insulin aspart	HUMALOG; HUMALOG JUNIOR, KWIKPEN, TEMPO PEN (insulin lispro)	
insulin aspart protamine mix 70/30 vial	HUMALOG MIX KWIKPEN 50/50, 75/25 (insulin lispro/lispro protamine)	<p>BASAGLAR</p> <ul style="list-style-type: none"> Requires clinical review
insulin lispro	HUMULIN 70/30 KWIKPEN (insulin N/regular)	
insulin lispro protamine mix 75/25 vial	HUMULIN N KWIKPEN (insulin N)	
LANTUS (insulin glargine)	insulin degludec	
TOUJEO (insulin glargine)	insulin glargine	
TOUJEO MAX (insulin glargine)	insulin glargine-yfgn	
	KIRSTY (insulin aspart-xjhz)	
	LEVEMIR (insulin detemir)	
	LYUMJEV (insulin lispro-aabc)	
	MERIOLOG (insulin aspart-szjj)	
	NOVOLIN 70/30 (insulin NPH/regular)	
	NOVOLIN N (insulin NPH)	
	NOVOLIN R (insulin regular)	
	NOVOLOG (insulin aspart)	
	NOVOLOG MIX 70/30 (insulin aspart protamine/aspart)	
	REZVOGLAR (insulin glargine-aglr)	
	SEMGLEE (insulin glargine-yfgn)	
	TRESIBA (insulin degludec)	

HYPOGLYCEMICS, MEGLITINIDES ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
nateglinide		
repaglinide		
HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 (SGLT-2) INHIBITORS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SGLT-2 INHIBITORS		Non-Preferred Criteria <ul style="list-style-type: none"> • Have tried 2 different preferred SGLT-2 inhibitors in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
FARXIGA (dapagliflozin)	dapagliflozin	
JARDIANCE (empagliflozin)	INPEFA (sotagliflozin)	
	INVOKANA (canagliflozin)	
	STEGLATRO (ertugliflozin)	
SGLT-2 INHIBITOR COMBINATIONS		
GLYXAMBI (empagliflozin/linagliptin)	dapagliflozin/metformin ER	
SYNJARDY (empagliflozin/metformin)	dapagliflozin/saxagliptin	
SYNJARDY XR (empagliflozin/metformin)	INVOKAMET (canagliflozin/metformin)	
TRIJARDY XR (empagliflozin/linagliptin/metformin)	INVOKAMET XR (canagliflozin/metformin)	
	SEGLUROMET (ertugliflozin/metformin)	
	STEGLUJAN (ertugliflozin/sitagliptin)	
	XIGDUO XR (dapagliflozin/metformin)	
HYPOGLYCEMICS, THIAZOLIDINEDIONES (TZDs) and TZD Combinations		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
pioglitazone	ACTOPLUS MET (pioglitazone/metformin)	
pioglitazone/metformin	ACTOS (pioglitazone)	
pioglitazone/glimepiride	DUETACT (pioglitazone/glimepiride)	
IDIOPATHIC PULMONARY FIBROSIS ^{DUR+}		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
OFEV (nintedanib)	ESBRIET (pirfenidone)	All Agents <ul style="list-style-type: none"> • Documented diagnosis of Idiopathic Pulmonary Fibrosis
pirfenidone	JASCAYD (nerandomilast)	
	nintedanib	OFEV <ul style="list-style-type: none"> • Documented diagnosis of Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, or Systemic Sclerosis-associated Interstitial Lung Disease OR • 90 days of therapy with Ofev in the past 105 days pirfenidone <ul style="list-style-type: none"> • Documented diagnosis of Idiopathic Pulmonary Fibrosis OR • 90 days of therapy with pirfenidone or Esbriet in the past 105 days

		ESBRIET, nintedanib <ul style="list-style-type: none"> Requires clinical review JASCAYD MANUAL PA
--	--	---

IMMUNE GLOBULINS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BIVIGAM	ALYGLO	
FLEBOGAMMA	ASCENIV	
GAMASTAN	CABLIVI	
GAMMAGARD	CUTAQUIG	
GAMMAGARD S-D	CUVITRU	
GAMUNEX-C	GAMMAGARD ERC ^{NR}	
HIZENTRA	GAMMAKED	
HYQVIA	GAMMAPLEX	
PANZYGA	OCTAGAM	
PRIVIGEN	QIVIGY ^{NR}	
XEMBIFY		

IMMUNOLOGIC THERAPIES FOR ASTHMA

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
DUPIXENT (dupilumab) <small>DUR+</small>	NUCALA (mepolizumab)	DUPIXENT <ul style="list-style-type: none"> 1 claim with DUPIXENT in the past 60 days OR New starts require clinical review (see manual PA links below) <ul style="list-style-type: none"> Allergic Fungal Rhinosinusitis MANUAL PA Asthma MANUAL PA Atopic Dermatitis MANUAL PA Bullous Pemphigoid MANUAL PA COPD MANUAL PA Chronic Spontaneous Urticaria MANUAL PA Eosinophilic Esophagitis MANUAL PA Nasal Polyposis MANUAL PA Prurigo Nodularis MANUAL PA FASENRA <ul style="list-style-type: none"> Requires clinical review MANUAL PA NUCALA <ul style="list-style-type: none"> Requires clinical review TEZSPIRE <ul style="list-style-type: none"> Requires clinical review XOLAIR <ul style="list-style-type: none"> 1 claim with XOLAIR in the past 45 days OR New starts require clinical review <ul style="list-style-type: none"> Asthma MANUAL PA Chronic Spontaneous Urticaria MANUAL PA Nasal Polyposis MANUAL PA
FASENRA (benralizumab)	TEZSPIRE (tezepelumab-ekko)	
XOLAIR (omalizumab)		

IMMUNOSUPPRESSIVE AGENTS, ORAL

	azelastine/fluticasone	
	DYMISTA (azelastine/fluticasone)	
	RYALTRIS (olopatadine/mometasone)	
ANTIHISTAMINES		
azelastine	olopatadine	
	PATANASE (olopatadine)	
CORTICOSTEROIDS		
fluticasone	BECONASE AQ (beclomethasone)	
NASONEX 24 HOUR ALLERGY SPRAY ^{OTC}	flunisolide	
	mometasone	
	NASONEX (mometasone)	
	OMNARIS (ciclesonide)	
	QNASL (beclomethasone)	
	XHANCE (fluticasone)	
	ZETONNA (ciclesonide)	

IRON CHELATING AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
deferasirox (all manufacturers except those listed as non-preferred)	deferasirox (manufacturers starting with 45963, 62332)	JADENU and JADENU SPRINKLE MANUAL PA
deferiprone 500 mg tablet	deferiprone 1,000 mg tablet	
FERRIPROX (deferiprone)	EXJADE (deferasirox)	
	JADENU (deferasirox)	
	JADENU SPRINKLE (deferasirox)	

IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME AGENTS/SELECTED AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
IRRITABLE BOWEL SYNDROME CONSTIPATION ^{DUR+}		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 1 year: GATTEX • 6 years: LINZESS 72 mcg • 7 years: LINZESS 145 mcg • 18 years: AMITIZA, IBSRELA, LINZESS 290 mcg, MOTTEGRITY, MOVANTIK, MYTESI, SYMPROIC, VIBERZI <p>Gender Limit</p> <ul style="list-style-type: none"> • Female AMITIZA 8 mcg
LINZESS (linaclotide)	AMITIZA (lubiprostone)	
lubiprostone	IBSRELA (tenapanor)	
	MOTTEGRITY (prucalopride)	
	MOVANTIK (naloxegol)	
	prucalopride	
	SYMPROIC (naldemedine)	
IRRITABLE BOWEL SYNDROME DIARRHEA		
dicyclomine	alosetron	
ED-SPAZ (hyoscyamine)	LOTRONEX (alosetron) ^{DUR+}	
hyoscyamine, hyoscyamine ER	VIBERZI (eluxadoline) ^{DUR+}	
HYOSYNE (hyoscyamine)		
LEVSIN, LEVSIN-SL (hyoscyamine)		
NULEV (hyoscyamine)		

OSCIMIN, OSCIMIN SL (hyoscyamine)		
SHORT BOWEL SYNDROME AND SELECTED GI AGENTS ^{DUR+}		
	GATTEX (teduglutide)	
	MYTESI (crofelemer)	
IRRITABLE BOWEL SYNDROME CONSTIPATION ^{DUR+}		
<p>Chronic Idiopathic Constipation (CIC): Amitiza 24 mcg, LINZESS, MOTEGRITY</p> <ul style="list-style-type: none"> • LINZESS 72 mcg <ul style="list-style-type: none"> ○ Age 6-17 years AND ○ Documented diagnosis pediatric functional constipation in the past year AND ○ No history of GI or bowel obstruction <p>OR</p> <ul style="list-style-type: none"> ○ Age 18 years or older AND ○ Documented diagnosis of CIC in the past year AND ○ No history of GI or bowel obstruction <ul style="list-style-type: none"> • LINZESS 145 mcg and lubiprostone 24 mcg <ul style="list-style-type: none"> ○ Age 18 years or older AND ○ Documented diagnosis of CIC in the past year AND ○ No history of GI or bowel obstruction • LINZESS 290 mcg <ul style="list-style-type: none"> ○ Age 18 years or older AND ○ Documented diagnosis of CIC in the past year AND ○ No history of GI or bowel obstruction AND ○ 1 claim with LINZESS 145 mcg in the past 45 days • Non-Preferred CIC Agents <ul style="list-style-type: none"> ○ Documented diagnosis of CIC AND 	<p>Irritable Bowel Syndrome Constipation Dominant (IBS-C): AMITIZA 8 mcg, IBSRELA, LINZESS 290 mcg</p> <ul style="list-style-type: none"> • Preferred IBS-C Agents <ul style="list-style-type: none"> ○ Documented diagnosis of IBS-C in the past year AND ○ No history of GI or bowel obstruction • Non-Preferred IBS-C Agents <ul style="list-style-type: none"> ○ Documented diagnosis of IBS-C in the past year AND ○ No history of GI or bowel obstruction AND ○ Have tried 2 preferred IBS-C agents in the past 6 months OR ○ 1 claim with the requested agent in the past 105 days 	<p>Opioid Induced Constipation (OIC): AMITIZA 24 mcg, MOVANTIK, SYMPROIC</p> <ul style="list-style-type: none"> • Preferred OIC Agents <ul style="list-style-type: none"> ○ Documented diagnosis of OIC and chronic pain in the past year AND ○ No history of GI or bowel obstruction AND ○ 1 claim for an opioid in the past 30 days • Non-Preferred OIC Agents <ul style="list-style-type: none"> ○ All preferred criteria met AND ○ Have tried 1 preferred OIC agents in the past 6 months OR ○ 1 claim with the requested agent in the past 105 days

<ul style="list-style-type: none"> ○ No history of GI or bowel obstruction AND ○ Have tried 2 preferred CIC agents in the past 6 months OR ○ 1 claim with the requested agent in the past 105 days 		
---	--	--

IRRITABLE BOWEL SYNDROME DIARRHEA

VIBERZI [New starts require clinical review]

- Documented diagnosis of IBS D in the past year **and** 1 claim for Viberzi in the past 105 days

LOTROXEX

- 1 claim for LOTROXEX in the past 105 days **OR**
- New starts require **MANUAL PA**

SHORT BOWEL SYNDROME AND SELECTED GI AGENTS ^{DUR+}

<p>HIV/AIDS Non-infectious Diarrhea</p> <ul style="list-style-type: none"> • MYTESI <ul style="list-style-type: none"> ○ Documented diagnosis of HIV/AIDS and non-infectious diarrhea in the past year AND ○ 1 claim for an antiretroviral in the past 30 days 	<p>Short Bowel Syndrome (SBS)</p> <ul style="list-style-type: none"> • GATTEX <ul style="list-style-type: none"> ○ 1 claim for GATTEX in the past 105 days OR ○ New starts require clinical review
--	---

LEUKOTRIENE MODIFIERS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
montelukast	ACCOLATE (zafirlukast)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 12 years: ZYFLO & ZYFLO CR <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
zafirlukast	SINGULAIR (montelukast)	
	zileuton	
	ZYFLO (zileuton)	

LIPOTROPICS, OTHER (NON-STATINS)

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACL INHIBITORS AND COMBINATIONS		JUXTAPID MANUAL PA
	NEXLETOL (bempedoic acid)	<p>KYNAMRO</p> <ul style="list-style-type: none"> • Requires clinical review
	NEXLIZET (bempedoic acid/ezetimibe)	
ANGIOPOIETIN-LIKE 3 INHIBITORS		<p>LEQVIO</p> <ul style="list-style-type: none"> • Requires clinical review
	EVKEEZA (evinacumab-dgnb)	<p>NEXLETOL and NEXLIZET</p> <ul style="list-style-type: none"> • Require clinical review
BILE ACID SEQUESTRANTS		
cholestyramine	colesevelam	<p>PRALUENT MANUAL PA</p> <p>REPATHA MANUAL PA</p>
cholestyramine light	COLESTID (colestipol)	
colestipol tablet	colestipol packet	
	PREVALITE (cholestyramine)	

	QUESTRAN (cholestyramine)	WELCHOL <ul style="list-style-type: none"> • Documented diagnosis of Type 2 Diabetes AND • 30 days of therapy with an antidiabetic agent in the past 6 months OR • 90 days of therapy with WELCHOL in the past 105 days
	QUESTRAN LIGHT (cholestyramine)	
	WELCHOL (colesevelam)	
CHOLESTEROL ABSORPTION INHIBITORS		
ezetimibe	ZETIA (ezetimibe)	
FIBRIC ACID DERIVATIVES		
fenofibrate	fenofibric acid	
gemfibrozil	FENOGLIDE (fenofibrate)	
	FIBRICOR (fenofibric acid)	
	LIPOFEN (fenofibrate)	
	LOPID (gemfibrozil)	
	TRICOR (fenofibrate)	
	TRILIPIX (fenofibric acid)	
MTP INHIBITOR		
	JUXTAPID (lomitapide)	
NIACIN		
niacin ER	niacin	
OMEGA-3 FATTY ACIDS		
omega-3 acid ethyl esters	icosapent ethyl	
	LOVAZA (omega-3 acid ethyl esters)	
PCSK-9 INHIBITORS		
REPATHA (evolocumab)	LEQVIO (inclisiran)	
	PRALUENT (alirocumab)	

LIPOTROPICS, STATINS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
STATINS DUR+		Minimum Age Limit <ul style="list-style-type: none"> • 10 years: ATORVALIQ Suspension Non-Preferred Criteria Statins <ul style="list-style-type: none"> • Have tried 2 different preferred statin or statin combination agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days Simvastatin <ul style="list-style-type: none"> • Daily doses ≥ 80 mg require clinical review
atorvastatin	ALTOPREV (lovastatin)	
lovastatin	ATORVALIQ (atorvastatin)	
pravastatin	CRESTOR (rosuvastatin)	
rosuvastatin	EZALLOR SPRINKLE (rosuvastatin)	
simvastatin	FLOLIPID (simvastatin)	
	fluvastatin	
	fluvastatin ER	
	LESCOL XL (fluvastatin)	
	LIPITOR (atorvastatin)	
	LIVALO (pitavastatin)	
	pitavastatin	
	ZOCOR (simvastatin)	
	ZYPITAMAG (pitavastatin)	
STATIN COMBINATIONS		
ezetimibe/simvastatin	amlodipine/atorvastatin	
	CADUET (amlodipine/atorvastatin)	
	VYTORIN (ezetimibe/simvastatin)	

MISCELLANEOUS BRAND/GENERIC

PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
ALLERGEN EXTRACT IMMUNOTHERAPY			<p>CUMULATIVE Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 31 tablets: alprazolam ER <p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 2 kits: epinephrine <p>EVRYSDI MANUAL PA</p> <p>PALSONIFY MANUAL PA</p> <p>RHAPSIDO MANUAL PA</p> <p>*The Miscellaneous subclass contains drugs that do not belong to any PDL drug classes. A non-preferred drug in this subclass may not require a documented history of preferred agents within the Miscellaneous subclass except for a brand name product with a generic equivalent.</p>
		GRASTEK	
		ORALAIR	
		RAGWITEK	
ANXIOLYTICS			
alprazolam		alprazolam ER	
hydroxyzine HCL		VISTARIL (hydroxyzine pamoate)	
hydroxyzine pamoate		XANAX, XANAX XR (alprazolam)	
EPINEPHRINE			
epinephrine (Mylan)		AUVI-Q (epinephrine)	
		epinephrine (all other manufacturers)	
		EPIPEN (epinephrine)	
		EPIPEN JR (epinephrine)	
		NEFFY (epinephrine)	
FAMILIAL CHYLOMICRONEMIA SYNDROME			
		REDEMPLO (plozasiran sodium) ^{NR}	
		TRYNGOLZA (olezarsen)	
MISCELLANEOUS*			
megestrol		BLUJEPA (gepotidacin)	
REVLIMID (lenalidomide)		BRINSUPRI (brensocatic)	
		CAMZYOS (mavacamten)	
		CRENESSITY (crinecerfont)	
		ERGOMAR (ergotamine)	
		EVRYSDI (risdiplam)	
		HARLIKU (nitisinone)	
		KORLYM (mifepristone)	
		lenalidomide	
		MYQORZO (aficamten) ^{NR}	
		PALSONIFY (paltusotine)	
		pomalidomide	
		POMALYST (pomalidomide)	
		RHAPSIDO (remibrutinib)	
		TARPEYO (budesonide)	
		VERQUVO (vericiguat)	
SUBLINGUAL NITROGLYCERIN			
nitroglycerin			
NITROLINGUAL (nitroglycerin)			
NITROSTAT (nitroglycerin)			
MOVEMENT DISORDER AGENTS ^{DUR+}			
PREFERRED AGENTS		NON-PREFERRED AGENTS	PA CRITERIA
AUSTEDO (deutetrabenazine)		INGREZZA INITIATION PACK (valbenazine)	<p>AUSTEDO and AUSTEDO XR</p> <ul style="list-style-type: none"> • Documented diagnosis of Huntington's chorea AND • 30 days of therapy with tetrabenazine in the past 180 days OR
AUSTEDO XR (deutetrabenazine)		XENAZINE (tetrabenazine)	

INGREZZA (valbenazine)		<ul style="list-style-type: none"> • 90 days of therapy with either agent in the past 105 days
INGREZZA SPRINKLE (valbenazine)		<ul style="list-style-type: none"> • Documented diagnosis of tardive dyskinesia AND • 90 days of therapy with either agent in the past 105 days OR • New starts require clinical review MANUAL PA
tetrabenazine		<p>INGREZZA and INGREZZA SPRINKLE</p> <ul style="list-style-type: none"> • Documented diagnosis of Huntington's chorea AND • 30 days of therapy with tetrabenazine in the past 180 days OR • 90 days of therapy with the requested agent in the past 105 days <ul style="list-style-type: none"> • Documented diagnosis of tardive dyskinesia AND • 90 days of therapy with the requested agent in the past 105 days OR • New starts require clinical review MANUAL PA

MULTIPLE SCLEROSIS AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HIGHLY ACTIVE		
TYSABRI (natalizumab)	BRIUMVI (ublituximab-xiyy)	<p>Preferred Agents</p> <ul style="list-style-type: none"> • Documented diagnosis of multiple sclerosis
	cladribine	
	KESIMPTA PEN (ofatumumab)	<p>Preferred Agents</p> <ul style="list-style-type: none"> • Documented diagnosis of multiple sclerosis
	MAVENCLAD (cladribine)	
	OCREVUS (ocrelizumab)	<p>Non-Preferred Criteria (Highly Active)</p> <ul style="list-style-type: none"> • Requires clinical review
	OCREVUS ZUNOVO (ocrelizumab/hyaluronidase-ocsq)	
	TYRUKO (natalizumab-sztn)	<p>Non-Preferred Criteria (Mildly Active)</p> <ul style="list-style-type: none"> • Documented diagnosis of multiple sclerosis AND • Have tried 2 different preferred agents in the past 6 months OR • 3 claims with the requested agent in the last 105 days
MODERATELY ACTIVE		
fingolimod	GILENYA (fingolimod)	<p>GILENYA, KESIMPTA, PONVORY, TASCENSO ODT, and ZEPOSIA</p> <ul style="list-style-type: none"> • Requires clinical review
	MAYZENT (siponimod)	
	PONVORY (ponesimod)	
	TASCENSO ODT (fingolimod)	
	ZEPOSIA (ozanimod)	
MILDLY ACTIVE		
BETASERON (interferon beta-1b)	AMPYRA (dalfampridine)	<p>cladribine and MAVENCLAD MANUAL PA</p>
COPAXONE (glatiramer) 20 mg	AUBAGIO (teriflunomide)	<p>MAYZENT MANUAL PA</p>
dalfampridine ER	AVONEX (interferon beta-1a)	<p>OCREVUS and OCREVUS ZUNOVO MANUAL PA</p>
dimethyl fumarate	BAFIERTAM (monomethyl fumarate)	
REBIF (interferon beta-1a)	COPAXONE (glatiramer) 40 mg	
REBIF REBIDOSE (interferon beta-1a)	glatiramer	
teriflunomide	GLATOPA (glatiramer)	
	PLEGRIDY (peginterferon beta-1a)	
	TECFIDERA (dimethyl fumarate)	

	VUMERITY (diroximel fumarate)	
MUSCULAR DYSTROPHY AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
EMFLAZA (deflazacort)	AGAMREE (vamorolone)	AGAMREE MANUAL PA
	AMONDYS-45 (casimersen)	AMONDYS-45 MANUAL PA
	deflazacort	
	DUVYZAT (givinostat)	DUVYZAT MANUAL PA
	ELEVIDYS (delandistrogene moxeparvovec-rokl)	ELEVIDYS MANUAL PA
	EXONDYS-51 (etepirsen)	EXONDYS MANUAL PA
	JAYTHARI (deflazacort)	JAYTHARI MANUAL PA
	KYMBEE (deflazacort)	KYMBEE MANUAL PA
	VILTEPSO (viltolarsen)	VILTEPSO MANUAL PA
	VYONDYS-53 (golodirsen)	VYONDYS MANUAL PA
NSAIDS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
COX II SELECTIVE		Quantity Limit (per 31 days) <ul style="list-style-type: none"> • 20 tablets: ketorolac tablets Non-Preferred Criteria <ul style="list-style-type: none"> • Requires clinical review
CELEBREX (celecoxib)	ELYXYB (celecoxib)	
celecoxib	meloxicam capsule	
meloxicam tablet	VYSCOXA (celecoxib)	
	ZYBIC (meloxicam) ^{NR}	
NON-SELECTIVE		
diclofenac sodium	COXANTO (oxaprozin)	
diclofenac sodium ER	DAYPRO (oxaprozin)	
EC-naproxen DR 500 mg tablet	diclofenac potassium	
etodolac tablet	DOLOBID (diflunisal)	
flurbiprofen	etodolac capsule, etodolac ER	
ibuprofen	FELDENE (piroxicam)	
indomethacin capsule	fenoprofen	
indomethacin ER	ibuprofen 300 mg	
ketorolac	indomethacin suppository	
nabumetone	ketoprofen	
naproxen 250 mg, 500 mg	LOFENA (diclofenac potassium)	
piroxicam	meclofenamate	
sulindac	mefenamic acid	
	NALFON (fenoprofen)	
	NAPRELAN (naproxen)	

	NAPROSYN 375 mg (naproxen)
	naproxen 375 mg, naproxen CR 375 mg, naproxen ER 500 mg
	ORUDIS (ketoprofen) ^{NR}
	oxaprozin
	RELAFEN DS (nabumetone)
	TOLECTIN (tolmetin)
	tolmetin
NSAID/GI PROTECTANT COMBINATIONS	
	ARTHROTEC 50 mg, 75 mg (diclofenac/misoprostol)
	diclofenac/misoprostol
	ibuprofen/famotidine
	naproxen/esomeprazole
	VIMOVO (naproxen/esomeprazole)

OPHTHALMIC AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANTIBIOTICS		
bacitracin/polymyxin	AZASITE (azithromycin)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 16 years: RESTASIS • 17 years: XIIDRA • 18 years: CEQUA, EYSUVIS, MIEBO, TRYPTYR, VEVYE <p>Quantity Limit (per 31 days)</p> <ul style="list-style-type: none"> • 2 mL: VEVYE • 3 mL: MIEBO • 5.5 mL: RESTASIS Multidose • 8.3 mL: EYSUVIS • 60 units: CEQUA, RESTASIS Droperette, TRYPTYR, XIIDRA • 1 bottle (150 mL): diclofenac 1.5% solution <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Anti-Inflammatory Agents <ul style="list-style-type: none"> ○ Have tried 2 different preferred agents in the past 6 months • Dry Eye Agents <ul style="list-style-type: none"> ○ History of 1 claim for both RESTASIS Droperette and XIIDRA in the past 6 months <p>BYQLOVI, MIEBO, RESTASIS Multidose, TRYPTYR, TYRVAYA, VEVYE</p> <ul style="list-style-type: none"> • Requires clinical review
ciprofloxacin	bacitracin	
erythromycin	besifloxacin ^{NR}	
gentamicin	BESIVANCE (besifloxacin)	
moxifloxacin	CILOXAN (ciprofloxacin)	
ofloxacin	gatifloxacin	
polymyxin B/trimethoprim	NATACYN (natamycin)	
tobramycin	neomycin/bacitracin/polymyxin	
	OCUFLOX (ofloxacin)	
	sulfacetamide	
	TOBEX (tobramycin)	
	VIGAMOX (moxifloxacin)	
ANTIBIOTIC-STEROID COMBINATIONS		
BLEPHAMIDE S.O.P. (sulfacetamide/prednisolone)	MAXITROL (neomycin/polymyxin/dexamethasone)	
neomycin/bacitracin/polymyxin/hydrocortisone	neomycin/polymyxin/gramicidin	
neomycin/polymyxin/dexamethasone	TOBRADEX ST (tobramycin/dexamethasone)	
PRED-G (gentamicin/prednisolone)	tobramycin/loteprednol ^{NR}	
sulfacetamide/prednisolone		
TOBRADEX (tobramycin/dexamethasone)		
tobramycin/dexamethasone		

ZYLET (tobramycin/loteprednol)		
ANTI-INFLAMMATORY AGENTS^{DUR+}		
dexamethasone	ACULAR, ACULAR LS (ketorolac)	
diclofenac sodium	ACUVAIL (ketorolac)	
difluprednate	bromfenac	
FLAREX (fluorometholone)	BROMSITE (bromfenac)	
fluorometholone	BYQLOVI (clobetasol)	
flurbiprofen	DUREZOL (difluprednate)	
FML FORTE (fluorometholone)	FML (fluorometholone)	
ketorolac	ILEVRO (nepafenac)	
MAXIDEX (dexamethasone)	INVELTYS (loteprednol)	
PRED MILD (prednisolone)	LOTEMAX, LOTE MAX SM (loteprednol)	
prednisolone acetate	loteprednol	
prednisolone sodium phosphate	NEVANAC (nepafenac)	
	PRED FORTE (prednisolone)	
	PROLENSA (bromfenac)	
DRY EYE AGENTS		
EYSUVIS (loteprednol)	CEQUA (cyclosporine)	
RESTASIS Droperette (cyclosporine)	cyclosporine	
XIIDRA (lifitegrast)	MIEBO (perfluorohehexyloactane)	
	RESTASIS Multidose (cyclosporine)	
	TYRVAYA (varenicline)	
	VEVYE (cyclosporine)	
OPHTHALMIC, GLAUCOMA AGENTS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BETA BLOCKERS		Minimum Age Limit <ul style="list-style-type: none"> • 18 years: IYUZEH Non-Preferred Criteria <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days
BETIMOL (timolol)	betaxolol	
carteolol	BETOPTIC S (betaxolol)	
ISTALOL (timolol)	timolol droperette, daily drop, gel	
levobunolol	TIMOPTIC; TIMOPTIC OCUDOSE, XE (timolol)	
timolol drops 0.25%, 0.5%		
CARBONIC ANHYDRASE INHIBITORS		
dorzolamide	AZOPT (brinzolamide) brinzolamide	
COMBINATION AGENTS		
COMBIGAN (brimonidine/timolol)	brimonidine/timolol	
dorzolamide/timolol	COSOPT (dorzolamide/timolol)	

SIMBRINZA (brinzolamide/brimonidine)	dorzolamide/timolol PF
PARASYMPATHOMIMETICS	
pilocarpine	PHOSPHOLINE IODIDE (echothiophate iodide)
PROSTAGLANDIN ANALOGS	
latanoprost	bimatoprost
	IYUZEH (latanoprost)
	LUMIGAN (bimatoprost)
	tafluprost
	TRAVATAN Z (travoprost)
	travoprost
	VYZULTA (latanoprostene bunod)
	XALATAN (latanoprost)
	XELPROS (latanoprost)
	ZIOPTAN (tafluprost)
	ZOLYMBUS (bimatoprost)
RHO KINASE INHIBITORS/COMBINATIONS	
RHOPRESSA (netarsudil)	
ROCKLATAN (netarsudil/latanoprost)	
SYMPATHOMIMETICS	
ALPHAGAN P (brimonidine)	brimonidine 0.1%, 0.15%
brimonidine 0.2%	

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ALREX (loteprednol)	ALOCRIL (nedocromil)	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> Have tried 2 different preferred agents in the past 6 months <p>VERKAZIA</p> <ul style="list-style-type: none"> Requires clinical review
azelastine	ALOMIDE (lodoxamide)	
cromolyn	bepotastine	
ketotifen ^{OTC}	BEPREVE (bepotastine)	
olopatadine	epinastine	
ZADITOR (ketotifen)	LASTACAFT (alcaftadine)	
	VERKAZIA (cyclosporine)	
	ZERVIAE (cetirizine)	

OPIATE DEPENDENCE TREATMENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
DEPENDENCE		Buprenorphine/naloxone provider summary found here
buprenorphine/naloxone SL tablet ^{DUR+}	BRIXADI (buprenorphine)	<p>Minimum Age Limit</p> <ul style="list-style-type: none"> 18 years: VIVITROL <p>SUBLOCADE MANUAL PA</p> <p>VIVITROL</p> <ul style="list-style-type: none"> Documented diagnosis of opioid related disorder Diagnosis of alcohol dependence requires MANUAL PA
naltrexone	buprenorphine ^{DUR+}	
SUBOXONE (buprenorphine/naloxone) ^{DUR+}	buprenorphine/naloxone film ^{DUR+}	
	lofexidine	
	LUCEMYRA (lofexidine)	
	SUBLOCADE (buprenorphine)	
	VIVITROL (naltrexone) ^{DUR+}	

	ZUBSOLV (buprenorphine/naloxone)	
TREATMENT		
KLOXXADO (naloxone)	LIFEMS NALOXONE (naloxone convenience kit)	
naloxone		
NARCAN (naloxone)		
OPVEE (nalmeffene)		
REXTOVY (naloxone)		
ZIMHI (naloxone)		

OTIC ANTIBIOTICS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CIPRO HC (ciprofloxacin/hydrocortison e)	ciprofloxacin	<p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 9 years: CIPRO HC and ciprofloxacin/hydrocortison e <p>Ciprofloxacin/Dexamethasone Suspension Criteria</p> <ul style="list-style-type: none"> • Age ≥ 6 months AND • Experiencing otorrhea secondary to recent, post-tympanostomy tube placement AND • Continued otorrhea after 10 days of otic treatment with ciprofloxacin ophthalmic solution and dexamethasone ophthalmic suspension
CORTISPORIN-TC (neomycin/colistin/hydrocortison e)	ciprofloxacin/dexamethason e	
fluocinolone	ciprofloxacin/fluocinolone	
neomycin/polymyxin/hydrocortison e	ciprofloxacin/hydrocortison e	
	DERMOTIC (fluocinolone)	
	FLAC OTIC OIL (fluocinolone)	
	hydrocortison e/acetic acid	
	OTOVEL (ciprofloxacin/fluocinolone)	

PANCREATIC ENZYMES

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CREON (lipase/protease/amylase)	VIOKACE (lipase/protease/amylase)	<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
PERTZYE (lipase/protease/amylase)		
ZENPEP (lipase/protease/amylase)		

PARATHYROID AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcitriol	doxercalciferol	
cinacalcet	RAYALDEE (calcifediol)	
ergocalciferol	ROCALTROL (calcitriol)	
paricalcitol	SENSIPAR (cinacalcet)	
ZEMPLAR (paricalcitol)	YORVIPATH (palopegteriparatide)	

PHOSPHATE BINDERS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
calcium acetate	AURYXIA (ferric citrate)	

CALPHRON (calcium acetate)	FOSRENOL (lanthanum)	
sevelamer carbonate tablet	lanthanum	
	MAGNEBIND (calcium carbonate/magnesium)	
	RENVELA (sevelamer)	
	sevelamer carbonate packet, sevelamer HCl	
	VELPHORO (sucroferric oxyhydroxide)	
	XPHOZAH (tenapanor)	

PLATELET AGGREGATION INHIBITORS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
aspirin/dipyridamole	BRILINTA (ticagrelor)	Non-Preferred Criteria <ul style="list-style-type: none"> Documented diagnosis AND Have tried 2 different preferred agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days ZONTIVITY MANUAL PA
cilostazol	EFFIENT (prasugrel)	
clopidogrel	PLAVIX (clopidogrel)	
dipyridamole		
pentoxifylline		
prasugrel		
ticagrelor		

PLATELET STIMULATING AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
NPLATE (romiplostim)	ALVAIZ (eltrombopag)	
PROMACTA (eltrombopag) tablet	DOPTELET (avatrombopag)	
	DOPTELET SPRINKLE (avatrombopag maleate)	
	MULPLETA (lusutrombopag)	
	PROMACTA (eltrombopag) packet	
	TAVALISSE (fostamatinib)	

POTASSIUM REMOVING AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LOKELMA (sodium zirconium cyclosilicate)	KIONEX (sodium polystyrene sulfonate)	
SPS (sodium polystyrene sulfonate) suspension	sodium polystyrene sulfonate	
	SPS (sodium polystyrene sulfonate) enema	
	VELTASSA (patiromer calcium sorbitex)	

PRENATAL VITAMINS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CLASSIC PRENATAL	All prenatal vitamins are non-preferred except for	
COMPLETE NATAL DHA		
COMPLETENATE		

CONCEPT DHA	those specifically indicated as preferred.	List of Preferred NDC's for Prenatal Vitamins can be found here
CONCEPT OB		
M-NATAL PLUS		
PRENATAL		
PRENATAL PLUS		
VITAMIN-MINERAL		
PRENATAL VITAMIN		
PRENATAL VITAMIN PLUS LOW IRON		
PRENATAL VITAMINS		
PROVIDA OB		
SELECT-OB + DHA		
SE-NATAL-19		
STUART ONE		
THRIVITE RX		
TRICARE		
TRINATAL RX 1		
VITAFOL FE PLUS		
VITAFOL ULTRA		
VITAFOL-OB		
VITAFOL-ONE		
WESNATAL DHA COMPLETE		
WESTAB PLUS		

PSEUDOBULBAR AFFECT AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	NUEDEXTA (dextromethorphan/quinidine)	Non-Preferred Criteria <ul style="list-style-type: none"> Documented diagnosis of pseudobulbar affect disorder OR 90 days of therapy with NUEDEXTA in the past 105 days

PULMONARY ANTIHYPERTENSIVE AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACTIVIN SIGNALING INHIBITORS		Minimum Age Limit <ul style="list-style-type: none"> 18 years: ADEMPAS, OPSYNVI, TADLIQ
	WINREVAIR (sotatercept-csrk)	
COMBINATION AGENTS		Maximum Age Limit <ul style="list-style-type: none"> 12 years: REVATIO suspension
	OPSYNVI (macitentan/tadalafil)	
ENDOTHELIN RECEPTOR ANTAGONISTS		Preferred Criteria <ul style="list-style-type: none"> PAH Agents <ul style="list-style-type: none"> Documented diagnosis of pulmonary hypertension Sildenafil tablets <ul style="list-style-type: none"> ≤ 1 year of age and documented diagnosis of pulmonary hypertension, patent ductus arteriosus, or persistent fetal circulation OR ≥ 1 year of age and documented diagnosis of pulmonary hypertension OR 90 days of therapy with the requested agent in the past 105 days Sildenafil suspension <ul style="list-style-type: none"> < 12 years of age AND Documented diagnosis of pulmonary hypertension, patent ductus arteriosus, or persistent fetal circulation, or a history of a heart transplant OR
ambrisentan	macitentan ^{NR}	
bosentan	OPSUMIT (macitentan)	
LETAIRIS (ambrisentan)	TRACLEER (bosentan)	
	TRYVIO (aprocitentan)	
PDE5 INHIBITORS		
sildenafil (generic REVATIO) tablet, suspension	ADCIRCA (tadalafil)	
tadalafil	ALYQ (tadalafil)	
	REVATIO (sildenafil)	
	TADLIQ (tadalafil)	

PROSTACYCLINS		<ul style="list-style-type: none"> • 90 days stable therapy with sildenafil suspension in the past 105 days <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Documented diagnosis of pulmonary hypertension AND • Have tried 1 preferred PAH agent in the past 6 months OR • 90 days of therapy with the requested agent in the past 105 days <p>OPSUMIT, OPSYNOVI, ORENITRAM ER, TYVASO, and VENTAVIS</p> <ul style="list-style-type: none"> • Require clinical review
	ORENITRAM ER (treprostinil)	
	ORENITRAM TITRATION PAK (treprostinil)	
	TYVASO (treprostinil)	
	VENTAVIS (iloprost)	
	YUTREPIA (treprostinil)	
SELECTIVE PROSTACYCLINE RECEPTOR AGONISTS		
	UPTRAVI (selexipag)	
SOLUBLE GUANYLATE CYCLASE STIMULATORS		
	ADEMPAS (riociguat)	

ADEMPAS

- Documented diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) or pulmonary arterial hypertension (WHO Group 1) **AND**
- Have tried 1 preferred PAH agent in the past 6 months **OR**
- 90 days of therapy with ADEMPAS in the past 105 days

TADLIQ

- Documented diagnosis of pulmonary hypertension **AND**
- Have tried preferred sildenafil suspension in the past 6 months **OR**
- 90 days of therapy with TADLIQ in the past 105 days

UPTRAVI

- Documented diagnosis of pulmonary hypertension **AND**
- Have tried 1 preferred endothelin receptor antagonist in the past 6 months **AND**
- Have tried 1 preferred PDE5 inhibitor in the past 6 months **OR**
- 90 days of therapy with UPTRAVI in the past 105 days

ROSACEA TREATMENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
metronidazole	AVAR (sulfacetamide sodium/sulfur)	<p>Note:</p> <ul style="list-style-type: none"> • Topical Sulfonamides used for Rosacea will require a manual PA for age > 21 years. • Other labeled indications are limited to < 21 years.
	AVAR LS (sulfacetamide sodium/sulfur)	
	AVAR-E (sulfacetamide sodium/sulfur)	
	BP 10-1 (sulfacetamide sodium/sulfur)	
	brimonidine	
	EPSOLAY (benzoyl peroxide)	
	FINACEA (azelaic acid)	
	METROCREAM (metronidazole)	
	METROGEL (metronidazole)	
	MIRVASO (brimonidine)	
	OVACE (sulfacetamide sodium)	
	OVACE PLUS (sulfacetamide sodium)	
	RHOFADE (oxymetazoline)	
	ROSADAN (metronidazole)	
	ROSULA (sulfacetamide sodium/sulfur)	

	sodium sulfacetamide
	sodium sulfacetamide/sulfur
	SOOLANTRA (ivermectin)
	SUMADAN (sulfacetamide sodium/sulfur)
	SUMADAN XLT (sulfacetamide sodium/sulfur/avob)
	SUMAXIN (sulfacetamide sodium/sulfur)
	SUMAXIN CP (sulfacetamide sodium/sulfur)
	SUMAXIN TS (sulfacetamide sodium/sulfur)

SEDATIVE HYPNOTIC AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
BENZODIAZEPINES DUR+		<p>MS DOM Opioid Initiative Criteria details found here</p> <ul style="list-style-type: none"> Concomitant use of Opioids and Benzodiazepines <p>Maximum Age Limit</p> <ul style="list-style-type: none"> 64 years: zolpidem 7.5 mg, 10 mg, and 12.5 mg <p>Gender and Dose Limit</p> <ul style="list-style-type: none"> Female: AMBIEN 5 mg, AMBIEN CR 6.25 mg, INTERMEZZO 1.75 mg Male: all strengths of zolpidem <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> Have tried 2 different preferred agents in the past 6 months <p>HETLIOZ capsules</p> <ul style="list-style-type: none"> Age 18 years or older AND Documented diagnosis of circadian rhythm sleep disorder OR Age 16 years and older AND Documented diagnosis of Smith-Magenis syndrome <p>HETLIOZ liquid</p> <ul style="list-style-type: none"> Age 3-15 years AND Documented diagnosis of Smith-Magenis syndrome <p>Note:</p> <ul style="list-style-type: none"> Single-source benzodiazepines and barbiturates are NOT covered. <ul style="list-style-type: none"> PA s will NOT be issued for these drugs. <p style="background-color: yellow;">See below for additional PA Criteria/DUR+ Rules</p>
estazolam	flurazepam	
temazepam 15 mg, 30 mg capsule	HALCION (triazolam)	
	quazepam	
	RESTORIL (temazepam)	
	temazepam 7.5 mg, 22.5 mg capsule	
	triazolam	
OTHERS DUR+		
eszopiclone	AMBIEN (zolpidem)	
ramelteon	AMBIEN CR (zolpidem)	
zaleplon	BELSOMRA (suvorexant)	
zolpidem tablet	DAYVIGO (lemborexant)	
	doxepin	
	EDULAR (zolpidem)	
	HETLIOZ LQ (tasimelteon)	
	LUNESTA (eszopiclone)	
	QUVIVIQ (daridorexant)	
	ROZEREM (ramelteon)	
	tasimelteon	
	zolpidem capsule	
	zolpidem sublingual tablet	
	zolpidem ER	

CUMULATIVE Quantity Limit Benzodiazepines

- 31 units/31 days:** Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

CUMULATIVE Quantity Limit Triazolam

- 10 units/31 days:** Quantity limit per rolling days for all strengths.
- 60 units/365 days:** Quantity limit per rolling days for all strengths.

CUMULATIVE Quantity Limit Non-Benzodiazepines

- **31 units/31 days:** Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

CUMULATIVE Quantity Limit HETLIOZ LQ

- **1 bottle (48 mL or 158 mL):** Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

CUMULATIVE Quantity Limit ZOLPIMIST

- **1 canister/31 days:** male; Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.
- **1 canister/62 days:** female; Quantity limit per rolling days for all strengths. DUR+ will allow an early refill override for one dose or therapy change per year.

SELECT CONTRACEPTIVE PRODUCTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
INJECTABLE CONTRACEPTIVES		<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • 1 claim with the requested agent in the past 105 days
medroxyprogesterone	DEPO-PROVERA (medroxyprogesterone)	
INTRAVAGINAL CONTRACEPTIVES		
ENILLORING (etonogestrel/ethinyl estradiol)	ANNOVERA (segesterone/ethinyl estradiol)	
NUVARING (etonogestrel/ethinyl estradiol)	PHEXXI (lactic acid/citric acid/potassium bitartrate)	
ORAL CONTRACEPTIVES ^{DUR+}		
All oral contraceptives are preferred except for those specifically indicated as non-preferred.	AMETHIA (levonorgestrel/ethinyl estradiol)	
	AMETHYST (levonorgestrel/ethinyl estradiol)	
	BALCOLTRA (levonorgestrel/ethinyl estradiol)	
	BEYAZ (drospirenone/ethinyl estradiol/levomefolate)	
	CAMRESE (levonorgestrel/ethinyl estradiol)	
	CAMRESE LO (levonorgestrel/ethinyl estradiol)	
	JOLESSA (levonorgestrel/ethinyl estradiol)	
	LO LOESTRIN FE (norethindrone/ethinyl estradiol/iron)	
LOESTRIN (norethindrone/ethinyl estradiol)		

	LOESTRIN FE (norethindrone/ethinyl estradiol/iron)	
	MINZOYA (levonorgestrel/ethinyl estradiol/iron)	
	NATAZIA (estradiol valerate/dienogest)	
	NEXTSTELLIS (drospirenone/estetrol)	
	OCELLA (ethinyl estradiol/drospirenone)	
	SAFYRAL (drospirenone/ethinyl estradiol/levomefolate)	
	SIMPESSE (levonorgestrel/ethinyl estradiol)	
	TAYTULLA (norethindrone/ethinyl estradiol/iron)	
	TYDEMY (drospirenone/ethinyl estradiol/levomefolate)	
	YASMIN (ethinyl estradiol/drospirenone)	
	YAZ (ethinyl estradiol/drospirenone)	
TRANSDERMAL CONTRACEPTIVES		
TWIRLA (levonorgestrel/ethinyl estradiol)	norelgestromin/ethinyl estradiol	
XULANE (norelgestromin/ethinyl estradiol)		
ZAFEMY (norelgestromin/ethinyl estradiol)		

SICKLE CELL AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CASGEVY (exagamglogene autotemcel)	ADAKVEO (crizanlizumab-tmca)	ENDARI MANUAL PA CASGEVY MANUAL PA LYFGENIA MANUAL PA
DROXIA (hydroxyurea)	ENDARI (glutamine)	
hydroxyurea	HYDREA (hydroxyurea)	
LYFGENIA (lovotibeglogene autotemcel)	l-glutamine	
	SIKLOS (hydroxyurea)	

SKELETAL MUSCLE RELAXANTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
------------------	----------------------	-------------

baclofen 5 mg, 10 mg, 20 mg tablet	AMRIX (cyclobenzaprine)	<p>Quantity Limit</p> <ul style="list-style-type: none"> • 84 tablets/180 days: carisoprodol <p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> • Documented diagnosis of an approvable indication AND • Have tried 2 different preferred agents in the past 6 months <p>Baclofen granules, solution, and suspension</p> <ul style="list-style-type: none"> • Require clinical review. <p>Carisoprodol</p> <ul style="list-style-type: none"> • Documented diagnosis of acute musculoskeletal condition AND • No history with meprobamate in the past 105 days AND • History of 1 claim for cyclobenzaprine in the past 21 days <p>AMRIX, ATMEKSI, cyclobenzaprine ER, metaxalone 640 mg, ONTRALFY, TANLOR, and tizanidine capsules</p> <ul style="list-style-type: none"> • Requires clinical review
chlorzoxazone	ATMEKSI (methocarbamol suspension)	
cyclobenzaprine 5 mg, 10 mg tablet	baclofen 15 mg tablet	
methocarbamol	baclofen suspension	
tizanidine tablet	carisoprodol	
	carisoprodol/aspirin	
	cyclobenzaprine 7.5 mg tablet	
	cyclobenzaprine ER	
	DANTRIUM (dantrolene)	
	dantrolene	
	FEXMID (cyclobenzaprine)	
	FLEQSUVY (baclofen)	
	LORZONE (chlorzoxazone)	
	LYVISPAH (baclofen)	
	metaxalone	
	NORGESIC (orphenadrine/aspirin/caffeine)	
	NORGESIC FORTE (orphenadrine/aspirin/caffeine)	
	ONTRALFY (tizanidine)	
	orphenadrine	
	orphenadrine/aspirin/caffeine	
	ORPHENGESIC FORTE (orphenadrine/aspirin/caffeine)	
	SOMA (carisoprodol)	
	TANLOR (methocarbamol)	
	tizanidine capsule	
	ZANAFLEX (tizanidine)	

SMOKING DETERRENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
NICOTINE TYPE		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 18 years: CHANTIX <p>Quantity Limit</p> <ul style="list-style-type: none"> • 336 tablets/year: CHANTIX 0.5 mg tabs, 1 mg tabs, and continuing pack • 2 treatment courses/year: CHANTIX Starter Pack
nicotine gum ^{OTC}	NICOTROL INHALER CARTRIDGE	
nicotine lozenge ^{OTC}	NICOTROL NASAL SPRAY	
nicotine patch ^{OTC}		
NON-NICOTINE TYPE		
bupropion SR		
CHANTIX (varenicline)		
varenicline		

STEROIDS (TOPICAL) ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
LOW POTENCY		Non-Preferred Criteria

alclometasone	fluocinolone
DERMA-SMOOTHIE-FS (fluocinolone)	hydrocortisone gel, lotion
desonide	HYDROXYM (hydrocortisone)
hydrocortisone cream, ointment, solution	MICORT-HC (hydrocortisone)
	PROCTOCORT (hydrocortisone)
MEDIUM POTENCY	
fluticasone	BESER (fluticasone)
mometasone	CAPEX (fluocinolone)
PANDEL (hydrocortisone probutate)	clocortolone
prednicarbate cream	CLODERM (clocortolone)
	flurandrenolide
	fluticasone lotion
	LOCOID (hydrocortisone butyrate)
	prednicarbate ointment
	SYNALAR (fluocinolone)
HIGH POTENCY	
betamethasone dipropionate cream, lotion	amcinonide
betamethasone dipropionate augmented	betamethasone dipropionate ointment
betamethasone valerate	desoximetasone
fluocinolone	diflorasone
fluocinonide	Halcinonide
fluocinonide-E	HALOG (halcinonide)
triamcinolone cream, ointment, lotion	KENALOG (triamcinolone)
	TOPICORT (desoximetasone)
	triamcinolone spray
VERY HIGH POTENCY	
clobetasol cream, foam, gel, ointment, shampoo, solution	APEXICON E (diflorasone)
clobetasol-E	clobetasol emulsion
halobetasol cream and ointment	clobetasol 0.025% cream
	CLOBEX (clobetasol)
	CLODAN (clobetasol)
	DIPROLENE (betamethasone)
	halobetasol foam and lotion
	IMPEKLO (clobetasol)
	IMPOYZ (clobetasol) 0.025% cream
	LEXETTE (halobetasol)
	OLUX (clobetasol)
	TEMOVATE (clobetasol)
	TOVET (clobetasol)

- **Low Potency**

- Have tried 2 different preferred low potency agents in the past 6 months

- **Medium Potency**

- Have tried 2 different preferred medium potency agents in the past 6 months

- **High Potency**

- Have tried 2 different preferred high potency agents in the past 6 months

- **Very High Potency**

- Have tried 2 different preferred very high potency agents in the past 6 months

amcinonide, clobetasol 0.025%, hydrocortisone 2% gel, HYDROXYM, MICORT-HC, PROCTOCORT

- Requires clinical review.

ULTRAVATE (halobetasol)

STIMULANTS AND RELATED AGENTS ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
SHORT-ACTING		<p>Minimum Age Limit</p> <ul style="list-style-type: none"> • 3 years: ADDERALL, EVEKEO, PROCENTRA, ZENZEDI • 6 years: ADDERALL XR, ADHANSIA XR, ADZENYS ER SUSPENSION, ADZENYS XR ODT, APTENSIO XR, ARYN TA, atomoxetine, AZSTARYS, clonidine ER, CONCERTA ER, COTEMPLA XR ODT, DAYTRANA, DESOXYN, DEXEDRINE, DYANA VEL XR, EVEKEO ODT, FOCALIN, FOCALIN XR, JORNAY PM, METADATE CD, METHYLIN, ONYDA XR, QELBREE, QUILLICHEW, QUILLIVANT XR, RELEXXII ER, RITALIN LA, VYVANSE, WAKIX, XELSTRYM • 7 years: XYREM • 13 years: MYDAYIS • 16 years: modafinil • 18 years: armodafinil, SUNOSI <p>Maximum Age Limit</p> <ul style="list-style-type: none"> • 18 years: clonidine ER, COTEMPLA XR ODT, DAYTRANA, EVEKEO ODT, guanfacine ER <p>Quantity Limit Stimulants (per 31 days)</p> <ul style="list-style-type: none"> • 31 tablets: ADDERALL XR, ADHANSIA XR, ADZENYS XR ODT, APTENSIO XR, AZSTARYS, CONCERTA ER 18, 27, & 54 mg, COTEMPLA XR-ODT 8.6 mg, DAYTRANA, DEXEDRINE Spansule, DYANA VEL XR Tablet, FOCALIN XR, JORNAY PM, METADATE CD, METHYLIN ER, MYDAYIS 37.5 mg & 50 mg, QUILLICHEW, RELEXXII ER, RITALIN LA & SR, VYVANSE, XELSTRYM • 62 tablets: ADDERALL, CONCERTA ER 36 mg, COTEMPLA XR-ODT 17.3 & 25.9 mg, DESOXYN, EVEKEO, FOCALIN, METHYLIN, RITALIN, ZENZEDI • 248 mL: DYANA VEL XR Suspension • 310 mL: METHYLIN, PROCENTRA • 372 mL: QUILLIVANT XR <p>Quantity Limit Narcolepsy (per 31 days)</p> <ul style="list-style-type: none"> • 31 tablets: armodafinil 150, 200 & 250 mg, modafinil 200 mg, SUNOSI • 46.5 tablets: modafinil 100 mg • 62 tablets: armodafinil 50 mg, WAKIX <p>Quantity Limit Non-Stimulants (per 31 days)</p> <ul style="list-style-type: none"> • 31 tablets: atomoxetine, guanfacine ER • 93 tablets: QELBREE 200 mg • 124 tablets: clonidine ER • 1 bottle (30 mL or 60 mL): ONYDA XR Suspension <p>ARYN TA</p> <ul style="list-style-type: none"> • Requires clinical review
dexmethylphenidate	ADDERALL (dextroamphetamine/amphetamine)	
dextroamphetamine	amphetamine	
dextroamphetamine/amphetamine	EVEKEO (amphetamine)	
methylphenidate tablet, solution	dextroamphetamine solution	
PROCENTRA (dextroamphetamine)	EVEKEO ODT (amphetamine)	
	FOCALIN (dexmethylphenidate)	
	methamphetamine	
	METHYLIN (methylphenidate)	
	methylphenidate chewable tablet	
	RITALIN (methylphenidate)	
	ZENZEDI (dextroamphetamine)	
LONG-ACTING		
ADDERALL XR (dextroamphetamine/amphetamine)	ADZENYS XR ODT (amphetamine)	
CONCERTA (methylphenidate)	amphetamine ER ODT (generic ADZENYS XR ODT)	
dexmethylphenidate ER	APTENSIO XR (methylphenidate)	
dextroamphetamine ER	ARYN TA (lisdexamfetamine) solution ^{NR}	
dextroamphetamine/amphetamine ER (generic ADDERALL XR)	AZSTARYS (serdexmethylphenidate/dexmethylphenidate)	
DYANA VEL XR (amphetamine) suspension	COTEMPLA XR ODT (methylphenidate)	
lisdexamfetamine	DAYTRANA (methylphenidate)	
methylphenidate CD	DEXEDRINE (dextroamphetamine)	
methylphenidate ER tablet	dextroamphetamine/amphetamine ER (generic MYDAYIS ER)	
methylphenidate LA	DYANA VEL XR (amphetamine) tablets	
QUILLICHEW ER (methylphenidate)	FOCALIN XR (dexmethylphenidate)	

QUILLIVANT XR (methylphenidate)	JORNAY PM (methylphenidate)
VYVANSE (lisdexamfetamine) capsules	methylphenidate patch
	methylphenidate ER capsule
	MYDAYIS (dextroamphetamine/amphe tamine)
	RELEXXII (methylphenidate)
	RITALIN LA (methylphenidate)
	VYVANSE (lisdexamfetamine) chewable tablets
	XELSTRYM (dextroamphetamine)
NARCOLEPSY	
armodafinil	NUVIGIL (armodafinil)
modafinil	PROVIGIL (modafinil)
SUNOSI (solriamfetol)	sodium oxybate
XYREM (sodium oxybate)	WAKIX (pitolisant)
	XYWAV (calcium/magnesium/potassi um/sodium oxybate)
NON-STIMULANTS	
atomoxetine	INTUNIV (guanfacine)
clonidine ER (generic Kapvay only)	ONYDA XR (clonidine)
guanfacine ER	STRATTERA (atomoxetine)
QELBREE (viloxazine)	

**Non-Preferred Short Acting Criteria
ADD/ADHD**

- Documented diagnosis of ADD/ADHD **AND**
- Have tried 2 different preferred Short Acting agents in the past 6 months **OR**
- 1 claim for a 30-day supply with the requested agent in the past 105 days

Narcolepsy: ADDERALL, EVEKEO, METHYLIN, PROCENTRA, RITALIN, ZENZEDI

- Documented diagnosis of narcolepsy **AND**
- 30 days of therapy with preferred modafinil or armodafinil in the past 6 months **AND**
- 1 preferred agent indicated for narcolepsy in the past 6 months **OR**
- Have tried 1 claim for a 30-day supply with the requested agent in the past 105 days

**Non-Preferred Long Acting Criteria
ADD/ADHD**

- Documented diagnosis of ADD/ADHD **AND**
- Have tried 2 different preferred Long-Acting agents in the past 6 months **OR**
- 1 claim for a 30-day supply with the requested agent in the past 105 days

Narcolepsy: ADDERALL XR, APTENSIO XR, CONCERTA ER, DEXEDRINE, METADATE CD, METHYLIN ER, MYDAYIS, NUVIGIL, PROVIGIL, QUILLICHEW, QUILLIVANT XR, RITALIN LA

- Documented diagnosis of narcolepsy **AND**
- 30 days of therapy with preferred modafinil or armodafinil in the past 6 months **AND**
- 1 different preferred agent indicated for narcolepsy in the past 6 months **OR**
- 1 claim for a 30-day supply with the requested agent in the past 105 days

Armodafinil

- Documented diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder, or bipolar depression

Atomoxetine

- Age ≥ 21 years **AND**
- Documented diagnosis of ADD/ADHD

Clonidine ER

- Documented diagnosis of ADD/ADHD

Guanfacine ER

- Documented diagnosis of ADD/ADHD

JORNAY PM

- Diagnosis of ADD/ADHD **AND**
- History of 84 days of therapy with 2 different preferred LA methylphenidate products in the past 12 months **AND**
- History of 84 days of therapy with 1 preferred non-methylphenidate LA stimulant in the past 12 months **OR**
- History of 84 days of therapy with JORNAY PM in the past 105 days

Modafinil

- Documented diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder, depression, sleep deprivation or Steinert Myotonic Dystrophy Syndrome

ONYDA XR MANUAL PA**QELBREE 100 mg**

- Quantity of 1 per day **AND**
- Documented diagnosis of ADD/ADHD **AND**
- No history of a different strength of QELBREE in the past 26 days **AND**
- 30 days of therapy with a preferred ADHD agent in the past 105 days **OR**
- 30 days of therapy with QELBREE in the past 105 days

QELBREE 150 mg

- Quantity of ≤ 2 per day **AND**
- Documented diagnosis of ADD/ADHD **AND**
- No history of a different strength of QELBREE in the past 26 days **AND**
- 30 days of therapy with a preferred ADHD agent in the past 105 days **OR**
- 30 days of therapy with QELBREE in the past 105 days

QELBREE 200 mg

- Age 18 years and older **AND**
- Quantity of ≤ 3 per day **AND**
- Documented diagnosis of ADD/ADHD **AND**
- No history of a different strength of QELBREE in the past 26 days **AND**
- 30 days of therapy with a preferred ADHD agent in the past 105 days **OR**
- Age 6-17 years **AND**
- Quantity of ≤ 2 tablets per day **AND**
- Documented diagnosis of ADD/ADHD **AND**
- No history of a different strength of Qelbree in the past 26 days **AND**
- 30 days of therapy with a preferred ADHD agent in the past 105 days **OR**
- 30 days of therapy with QELBREE in the past 105 days

SUNOSI

- Documented diagnosis of narcolepsy or obstructive sleep apnea **AND**
- 30 days of therapy with preferred modafinil or armodafinil in the past 6 months

VYVANSE

- Documented diagnosis of binge eating disorder or ADD/ADHD **OR**
- 90 days of therapy with Vyvanse in the past 105 days

WAKIX

- Requires clinical review

XYREM

- Diagnosis of narcolepsy or excessive daytime sleepiness **OR**
- 30 days of therapy with this agent in the past 105 days

XYWAV

- Requires clinical review

TETRACYCLINES ^{DUR+}

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
doxycycline hyclate	demeclocycline	Non-Preferred Agents <ul style="list-style-type: none"> • Have tried 2 different preferred agents in the past 6 months
doxycycline monohydrate capsule	DORYX (doxycycline hyclate)	

minocycline capsule	DORYX MPC (doxycycline hyclate)	<p>Demeclocycline</p> <ul style="list-style-type: none"> Documented diagnosis of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) will allow for automatic approval <p>ORACEA</p> <ul style="list-style-type: none"> Requires clinical review
tetracycline capsule	doxycycline hyclate DR	
	doxycycline IR/DR	
	doxycycline monohydrate suspension, tablet	
	LYMEPAK (doxycycline hyclate)	
	MINOCIN (minocycline)	
	minocycline tablet	
	minocycline ER	
	MINOLIRA ER (minocycline)	
	MORGIDOX (doxycycline hyclate)	
	NUZYRA (omadacycline)	
	ORACEA (doxycycline monohydrate)	
	SOLODYN (minocycline)	
	tetracycline tablet	

ULCERATIVE COLITIS & CROHN'S AGENTS ^{DUR+} *See Cytokine & CAM Antagonists Class for Additional Agents*

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ORAL		<p>Non-Preferred Criteria</p> <ul style="list-style-type: none"> Documented diagnosis of Ulcerative Colitis AND Have tried 2 different preferred agents in the past 6 months OR 90 days of therapy with the requested agent in the past 105 days <p>VELSIPITY</p> <ul style="list-style-type: none"> Requires clinical review
balsalazide	AZULFIDINE (sulfasalazine)	
budesonide	DELZICOL (mesalamine)	
PENTASA (mesalamine)	DIPENTUM (olsalazine)	
sulfasalazine	LIALDA (mesalamine)	
sulfasalazine DR	mesalamine	
	mesalamine DR, mesalamine ER	
	VELSIPITY (etrasimod)	
RECTAL		
mesalamine suppository	budesonide	
	CANASA (mesalamine)	
	mesalamine enema	
	ROWASA (mesalamine)	
	SFROWASA (mesalamine)	

UREA CYCLE DISORDER AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
CARBAGLU (carglumic acid)	BUPHENYL (sodium phenylbutyrate)	
	carglumic acid	
	glycerol phenylbutyrate	
	OLPRUVA (sodium phenylbutyrate)	
	PHEBURANE (sodium phenylbutyrate)	
	RAVICTI (glycerol phenylbutyrate)	